

ARIZONA ARBOVIRAL HANDBOOK FOR CHIKUNGUNYA, DENGUE, AND ZIKA VIRUSES



Arizona Arboviral Handbook for Chikungunya, Dengue, and Zika Viruses

| | |
|---|-----------|
| OBJECTIVES | 4 |
| I: CHIKUNGUNYA | 5 |
| Chikungunya Ecology and Transmission | 6 |
| Chikungunya Clinical Disease and Case Management | 7 |
| Chikungunya Laboratory Testing | 8 |
| Chikungunya Case Definitions | 9 |
| II: DENGUE | 12 |
| Dengue Ecology and Transmission..... | 14 |
| Dengue Clinical Disease and Case Management | 14 |
| Dengue Laboratory Testing | 17 |
| Dengue Case Definitions | 20 |
| Dengue Case Classification Algorithm | 24 |
| III: ZIKA | 27 |
| Zika Ecology and Transmission | 29 |
| Zika Clinical Disease and Case Management | 29 |
| Zika Laboratory Testing..... | 30 |
| Zika Case Definitions | 33 |
| IV. CHIKUNGUNYA, DENGUE, AND ZIKA COMPARISON | 40 |
| Recommendations for Healthcare Providers | 41 |
| V: PLANNING AND RESPONSE SCENARIOS | 43 |
| Recommended Response Activities by Epidemiologic Scenario | 45 |
| VI: PUBLIC HEALTH SURVEILLANCE AND RESPONSE | 49 |
| Reporting and Agency Roles | 49 |
| Surveillance and Investigation Guidelines..... | 50 |

Other Planning Considerations 53

Incident Command System..... 54

Public Health Response Scenarios 54

Aedes aegypti Epidemiology 57

Vector Surveillance Background 58

Vector Surveillance Guidelines..... 64

Vector Control Guidelines 66

Recommendations for Local Vector Control Staff 69

Mosquito Surveillance Platform 69

Legal Authority for Vector Control Response..... 69

The Role of Public Education 70

VIII: OUTBREAK COMMUNICATIONS..... 71

Public Information During a Potential or Ongoing Outbreak: 71

Communication Response Scenarios 73

IX: APPENDIX 75

Investigation Forms.....75

ADHS Educational Materials and Resources.....75

ADHS and County Health Department Contacts76

References77


Epidemiological Profiles.....84

OBJECTIVES

The goal of this document is to outline a preparation and response plan for emerging arboviral threats in Arizona. With the expansion of chikungunya, dengue, and Zika viruses into the Caribbean and Latin America, there is an increasing risk for travelers to return to Arizona infected with one these viruses. All three of these diseases have potential for local transmission in Arizona, and this document was written in response to these encroaching threats.

This document includes detailed sections about chikungunya, dengue, and Zika background, clinical information, surveillance programs, and laboratory testing. The remainder of the handbook is applicable to prevention, investigation, and control of dengue, chikungunya, and Zika viruses. This includes suggested guidelines for public health officials, vector control agencies, and healthcare professionals. Points of contact and additional resources are also provided. This document was developed based on guidelines from the Pan American Health Organization (PAHO)/Centers for Disease Control and Prevention (CDC) Preparedness and Response for Chikungunya Virus Introduction in the Americas, the World Health Organization (WHO) Dengue Guidelines for Diagnosis, Treatment, Prevention and Control, and CDC's Zika Interim Response Plan. Links to these documents are available in the references.

Thanks to all state and local partners who provided content or edits to this document.



Transmission electron micrograph of chikungunya virus particles, CDC

I: CHIKUNGUNYA

Chikungunya fever is a mosquito-borne disease caused by a virus in the Alphavirus genus, *Togaviridae* family¹⁻⁴. Chikungunya virus is primarily transmitted by *Aedes aegypti* and *Aedes albopictus* mosquitoes, which can also transmit dengue, Zika, and yellow fever viruses¹⁻⁵. Beginning in 2004, chikungunya has caused large outbreaks in Africa, Asia, Indian Ocean islands, and in Italy^{4,6}. Attack rates in these outbreaks ranged from 38-63% and have reached over 500,000 cases in multiple outbreaks^{4,6}.

In late 2013, the first cases of locally acquired chikungunya in the western hemisphere were reported among residents of St. Martin in the Caribbean^{7,8}. The virus quickly began to spread across the Caribbean region, and locally acquired cases have been reported from North, Central, and South America⁹. Isolated cases of local transmission of chikungunya were reported in Florida and Texas during 2014 and 2015, respectively, but no locally-transmitted cases were reported in 2016⁹.

Two distinct lineages of chikungunya have been identified — the Indian Ocean lineage and the Asian lineage^{3,8}. The Indian Ocean lineage is the strain currently circulating in the Americas, and has demonstrated less efficient transmission among *Aedes albopictus* mosquitoes than the Asian lineage^{3,8}. This difference might indicate lower risk for transmission in areas with only *Aedes albopictus* mosquitoes^{3,8}.

Chikungunya in Arizona

The introduction of chikungunya virus to the Americas increases the risk for disease importation to the United States. Arizona is at risk for local transmission of chikungunya virus because of the presence of *Ae. aegypti* mosquitoes¹⁰. Local transmission could occur if a person was infected while traveling, and then bitten by local mosquitoes of the appropriate species after returning⁴. This infected mosquito could then spread the virus to other people, who would be considered locally acquired cases⁴. Infected mosquitoes could also potentially travel across state or national borders, although this would be unlikely due to the short flight range of *Aedes aegypti*¹¹. An epidemiological profile of chikungunya cases in Arizona from 2008 through 2016 is available in the Appendix.


A more detailed look at the *Aedes aegypti* vector in Arizona, and how to implement surveillance and control methods, are found in section VII of this document.

Chikungunya Ecology and Transmission

Reservoirs

Humans serve as the primary reservoir for chikungunya, but several other vertebrate species

have been implicated as potential reservoirs, including non-human primates, rodents,



Countries and territories where chikungunya cases have been reported (as of April 22, 2016)⁹.

birds, and some small mammals^{2,4}. Animal reservoirs are not considered to play a significant role in transmission during outbreaks⁴.

Incubation periods

- **Humans: 3–7 days** (range: 1–12) between the bite of an infected mosquito and when symptoms begin (intrinsic incubation)^{1,4,6,12}.
- **Mosquitoes: ~10 days, on average**, between intake of an infected blood meal and when mosquitoes can transmit the virus to a naïve human host (extrinsic incubation)⁴.

Susceptibility

All persons not previously infected with chikungunya virus are at risk for infection and disease⁴. This can occur anywhere where infected *Aedes* spp. mosquitoes are present. Due to the immunological naiveté of Arizona's population, all areas with known populations of *Aedes* vector mosquitoes are considered at risk for local transmission⁴. It is believed that once exposed, individuals will develop long-lasting protective immunity⁴.

Chikungunya Clinical Disease and Case Management

A person who is bitten by an infected mosquito usually develops signs and symptoms of disease 3–7 days after the bite (range 1–12 days)^{1,4,6,12}. Most individuals (73–97%) develop symptomatic infection; however, some remain asymptomatic^{4,6}. Chikungunya can cause acute, subacute, and chronic disease^{2,4,6,12}.

Acute chikungunya fever usually lasts 3–10 days and is characterized by a sudden onset of high fever (usually >102°F) and severe joint pain^{1,2,4,6,12}. Fever can last from several days up to a week, and is sometimes intermittent^{4,6}. Joint pain is usually symmetric, and most commonly seen in the hands and feet, but can manifest in other joints as well^{1,4,6,12}. Other signs and symptoms can include headache, diffuse back pain, myalgia, nausea, vomiting, polyarthritis, tenosynovitis, rash, and conjunctivitis^{1,2,4,6,12}. About 50% of patients develop a rash 2–5 days after fever onset⁴. The rash is typically maculopapular and involves the trunk and extremities, but can also occur on the hands and feet^{4,6}. Fatalities are extremely rare (<1% of cases), but when they do occur it is often among the elderly, newborn, or those with comorbidities^{1,12,13}. Morbidity due to joint pain and swelling can be severe and impact the person's ability to walk or return to work^{1,2,4,6,12}. These symptoms typically only last a few weeks, but in some cases have been shown to last for months or even years^{1,2,4,6,12}.

Abnormal laboratory findings can include thrombocytopenia, leukopenia, and elevated liver function tests^{1,4,6,12}.

Atypical manifestations of chikungunya can occur and include neurological, ocular, cardiovascular, dermatological, renal, or other complications^{1,2,4,6,12}.

Treatment

Treatment for acute chikungunya fever is supportive therapy; however, healthcare providers should first exclude more serious conditions such as malaria, dengue, yellow fever, and bacterial infections that would require more specific treatment^{1,2,4,6,12}. Nonsteroidal anti-inflammatories (NSAIDs) and acetylsalicylic acid (Aspirin) should be avoided until dengue has been ruled out as possible diagnosis due to the risk of hemorrhagic complications and Reyes Syndrome^{1,2,4,6,12}.

Chronic Chikungunya Infection

Patients with chikungunya often improve after the first 10 days of symptoms, but can experience symptom recurrence 2–3 months after initial infection^{4,12}. This usually presents as various rheumatic symptoms including distal polyarthrititis, exacerbation of pain in previously injured joints and bones, and tenosynovitis in wrists and ankles⁴. Vascular manifestations can occur, such as Raynaud's syndrome^{4,6}. Many patients also complain of general depression, fatigue, and weakness⁴. Study results vary, but have suggested that after 3 months, 80–93% of patients complain of chronic or recurrent symptoms⁴. After 10 months, 49% of patients will complain of chronic symptoms⁴. Between 18 months and 36 months, 12–18% of patients will complain of chronic symptoms⁴. Chronic symptoms appear to be more common among persons 65 years of age or older, with preexisting joint conditions, and who experienced more severe acute stage disease¹².

Chikungunya Laboratory Testing

Laboratories

Several private commercial laboratories offer chikungunya testing. In addition, the Arizona State Public Health Laboratory (ASPHL) can perform polymerase chain reaction (PCR) and immunoglobulin (Ig) M Enzyme-linked immunosorbent assay (ELISA) testing for chikungunya virus¹⁴. If needed, testing can also be performed at the CDC Arboviral Disease Branch laboratory in Fort Collins, CO¹⁵.

Samples

Chikungunya testing is most commonly performed on blood or serum samples^{4,14,15}; cerebrospinal fluid can be tested in patients with meningoencephalitic symptoms⁴. Additional testing can be performed on other specimens in rare cases (i.e., autopsy material following a suspect chikungunya death), but there is little information on the detection of virus by isolation or reverse transcriptase-polymerase chain reaction (RT-PCR) from tissue or organs⁴. Several methods are available for chikungunya virus diagnostic assays, and include the following:

- Viral culture⁴
- RT-PCR⁴
- ELISA or immunofluorescence assay (IFA) for IgM or IgG antibodies⁴
- Plaque reduction neutralization tests (PRNT)⁴
 - Not routinely performed for initial diagnosis⁴
 - Results are more specific than ELISA/IFA results and are generally required to confirm diagnosis⁴
- Immunohistochemical staining (IHC)⁴
 - Performed on tissues⁴

For **routine** chikungunya virus diagnostic testing, serum specimens can be tested by RT-PCR and IgM antibody tests^{4,14,15}. To determine which test(s) are needed, identify the day after illness onset when the specimen is collected and use the following guidelines:

- **0–3 days: RT-PCR⁴**
- **4–6 days: both RT-PCR and IgM⁴**
- **≥7 days: IgM⁴**

Specimen Collection, Storage and Transportation

- Collect 4–5 ml of blood aseptically in a tube or a vial^{4,14,15}. Any serum separator vial is appropriate, such as a red top, orange top, or tiger top^{4,14,15}.
- Allow blood to clot at room temperature^{4,14,15}.
- Centrifuge blood at 2,000 rpm to separate serum, and then collect the serum in a clean dry vial⁴.
- Samples should be frozen or refrigerated, depending on the testing laboratory's recommendations⁴.

Chikungunya Case Definitions

Chikungunya falls under the arboviral disease case definition, as defined by the Council of State and Territorial Epidemiologists (CSTE)¹⁶. CSTE divides arboviral infection case classifications in two categories; neuroinvasive or non-neuroinvasive¹⁶. Because chikungunya is a predominantly non-neuroinvasive disease^{1,2,4,6,12}, we have only included the non-neuroinvasive criteria in this handbook. If a neuroinvasive disease is suspected, please see the complete arboviral disease case definition in the [Arizona Case Definitions for Public Health Surveillance](#)¹⁷.

Clinical Criteria^{16,17}

A clinically compatible case of chikungunya is defined as follows^{16,17}:

- Fever or chills as reported by the patient or a healthcare provider, AND^{16,17}
- Absence of more likely clinical explanation, AND^{16,17}

- Absence of neuroinvasive disease. Other clinically compatible symptoms including headache, myalgia, rash, arthralgia, vertigo, vomiting, paresis, and/or nuchal rigidity^{16,17}

Laboratory Criteria for Diagnosis^{16,17}


- Isolation of virus from, or demonstration of specific viral antigen or nucleic acid in, tissue, blood, CSF, or other body fluid, OR^{16,17}
- Four-fold or greater change in virus-specific quantitative antibody titers in paired sera, OR^{16,17}
- Virus-specific IgM antibodies in serum with confirmatory virus-specific neutralizing antibodies in the same or a later specimen, OR^{16,17}
- Virus-specific IgM antibodies in cerebrospinal fluid (CSF) or serum^{16,17}.

A confirmed case meets the above clinical criteria and one or more of the following laboratory criteria^{16,17}:

- Isolation of virus from, or demonstration of specific viral antigen or nucleic acid in, tissue, blood, CSF, or other body fluid, OR^{16,17}
- Four-fold or greater change in virus-specific quantitative antibody titers in paired sera, OR^{16,17}
- Virus-specific IgM antibodies in serum with confirmatory virus-specific neutralizing antibodies in the same or a later specimen^{16,17}.

A probable case meets the above clinical criteria and virus-specific IgM antibodies in serum but with no other testing^{16,17}.

Chikungunya Case Classification Algorithm






Female *Aedes aegypti* mosquito, CDC

II: DENGUE

Dengue fever is a mosquito-borne disease in the flavivirus genus of the Flaviviridae family¹⁸⁻²⁰. It is primarily transmitted by *Aedes aegypti* and *Aedes albopictus* mosquitoes, which also transmit chikungunya and Zika viruses¹⁸⁻²⁰. These vectors are found throughout the world, and their abundance has aided in the geographic expansion of the virus²¹. Dengue is expanding rapidly, and has had a 30-fold increase in incidence during 2000–2010²⁰. This includes increased disease incidence in endemic countries as well as encroachment into new countries and regions, such as the outbreak of locally-acquired cases of dengue occurred in Hawaii in 2015²⁰.

In many parts of the tropics and subtropics, dengue is endemic¹⁸⁻²¹. However, dengue also has significant epidemic potential^{20,21}. In order for dengue to become endemic three factors are required^{20,21}:

- A large population of *Aedes aegypti* or *Aedes albopictus* mosquitoes^{20,21}. Mosquito population growth can occur in response to increased rainfall or other environmental factors.
- A human population immunologically naïve to one or more of the dengue serotypes¹⁸⁻²¹.
- Contact between the human population and the infected vector population, creating a cycle of human-mosquito-human transmission¹⁸⁻²¹.




Counties/areas at risk of dengue transmission, 2008. (Figure 1.1 from the WHO’s Dengue: Guidelines for Diagnosis, Treatment Prevention, and Control)¹⁸.

Dengue in Arizona

The increasing incidence and geographic distribution of dengue increases the likelihood for travel-associated cases to occur in Arizona. Arizona is also at risk for local transmission of dengue virus because of the presence of *Ae. aegypti*¹⁰. Local transmission occurs if a traveler infected in a dengue-endemic area, is then then bitten by an *Aedes* spp. mosquito after returning to Arizona. Local transmission has been reported in Arizona for the first time in 2022 (see Kretschmer M, Collins J, Dale AP, et al. *Notes From the Field: First Evidence of Locally Acquired Dengue Virus Infection — Maricopa County, Arizona, November 2022*. [MMWR Morb Mortal Wkly Rep 2023;72:290–291](https://doi.org/10.15585/mmwr.mm7229a1)). Dengue-infected mosquitoes could also potentially travel across state or national borders. In 2014, locally acquired dengue cases in Sonora, Mexico were identified near the Arizona border region, and Sonora reported >3600 dengue cases. Due to this outbreak, a large increase in travel-associated dengue cases occurred among Arizona residents, with over 90 cases

reported²². An epidemiological profile of dengue cases in Arizona from 2008 through 2016 is available in the Appendix.



Aedes aegypti mosquitoes are established in Arizona. A more detailed look at the vectors of concern in Arizona, and how to perform surveillance and vector control, are found in section VII of this document.

Dengue Ecology and Transmission

Reservoirs

In endemic areas, dengue is maintained in a human-mosquito cycle¹⁸⁻²⁰. Sylvatic dengue strains are

Average annual number of dengue fever and dengue hemorrhagic fever cases reported to WHO, and countries reporting dengue, 1955-2007 (Figure 1.2 from the WHO's Dengue: Guidelines for Diagnosis, Treatment Prevention, and Control)¹⁸.

present in some area of Africa and Asia, which may occasionally spill-over and cause human infections¹⁸⁻²⁰.

Incubation period

- **Humans: 4–7 days** (range 3–14 days) between the bite of an infected mosquito and when symptoms begin (intrinsic incubation)^{18-21,23}.
- **Mosquitoes: 8-12 days** between intake of a dengue infected blood meal and when mosquitoes can transmit the virus to a naïve human host (extrinsic incubation)¹⁸⁻²¹.

Dengue Serotypes

Dengue fever is caused by any of the dengue serotypes I–IV¹⁸⁻²¹. Following infection, patients are protected from illness with the same serologic strain¹⁸⁻²¹. Unfortunately, upon a second infection with a *different* serotype, severe disease manifestations such as shock and hemorrhagic disease manifestations are more likely to occur¹⁸⁻²¹. This is attributable to the overreaction of the immune response to the dengue antigens¹⁸⁻²¹. The co-circulation of multiple virus serotypes in an area is termed **hyperendemicity**, and is associated with epidemic severe dengue in a geographical area²¹.

Dengue Clinical Disease and Case Management

The clinical manifestations of dengue fever can be divided into three phases: febrile phase, critical phase, and recovery phase^{20,21,23}.

Febrile Phase


Only about 1 out of every 4 people bitten by an infected mosquito will develop symptoms, which usually begin 4–7 days after exposure^{18-21,23}. Common symptoms include sudden high fever accompanied by facial flushing, rash, body aches, myalgia, arthralgia and headache^{18-21,23}. Sore throat, anorexia, nausea and vomiting are also common^{18-21,23}. This phase usually last 2–7 days^{18-21,23}. Many symptoms during this period are non-specific, but a positive [tourniquet test](#) should increase suspicion for dengue infection^{18-21,23}. Patients should be monitored closely for warning signs of more severe disease^{18-21,23}. Mild hemorrhagic manifestations are not uncommon, and include petechial and mucosal membrane bleeding^{18-21,23}. Gastrointestinal bleeding or massive vaginal bleeding in women of childbearing age is also possible^{18-21,23}. The liver can be enlarged and tender during the febrile period^{18-21,23}.

Critical Phase

During the critical phase of illness (days 3–7), the patient's fever often resolves concurrent with an increase in capillary permeability^{18-21,23}. This period of plasma leakage often lasts 24–48 hours^{18-21,23}. The level of capillary permeability determines disease progression and severity, and is highly variable^{20,21,23}. In more severe cases, this leads to pleural effusions and ascites^{20,21,23}. Shock occurs when a critical volume of plasma is lost through capillary leakage, and often coincides with a lowering of temperature, organ damage, metabolic acidosis, and disseminated intravascular coagulation or other coagulation abnormalities^{20,21,23}. The patient is considered in shock if their pulse pressure is ≤ 20 mm Hg^{20,21,23}. It is possible for patients to progress rapidly from the febrile phase to the critical phase without a drop in temperature, which is why patients should be monitored closely throughout the course of disease^{20,21,23}. A complete blood count can be used to determine the onset and severity of the critical phase and plasma leakage^{20,21,23}.

Recovery Phase

If the patient survives the critical phase, a 48–72 hour period of gradual reabsorption from the extravascular compartment fluid occurs^{18-21,23}. Patient wellbeing improves during this period^{18-21,23}. Bradycardia and electrocardiographic changes are common in this phase^{18-21,23}. It is important to avoid excessive fluid therapy, which is associated with pulmonary edema and congestive heart failure^{18-21,23}.



The course of dengue illness. (Figure 2.1 from the WHO’s Dengue: Guidelines for Diagnosis, Treatment Prevention, and Control)¹⁸.

| Phase | Duration | Clinical Concerns |
|-------------------------------------|---------------------------------|---|
| Febrile ^{20,21,23} | 2–7 days ^{20,21,23} | Dehydration and high fever; fever can lead to neurological disturbances or seizures in children ^{20,21,23} |
| Critical ^{20,21,23} | 24–48 hours ^{20,21,23} | Shock from plasma leakage, severe hemorrhage, organ impairment ^{20,21,23} |
| Recovery ^{20,21,23} | 48–72 hours ^{20,21,23} | Hypervolemia (following excessive fluid therapy) ^{20,21,23} |

Monitoring and Treatment

Clinical interventions should change based on disease manifestations^{18-21,23}. Vital signs, peripheral perfusion, urine output, hematocrit, blood glucose, and organ function should

be monitored in the febrile stage for signs of clinical deterioration and warning signs of more severe disease^{18-21,23}. Patients with critical phase signs including abdominal pain or tenderness, persistent vomiting, extravascular fluid accumulation (e.g., pleural or pericardial effusion, ascites), mucosal bleeding at any site, liver enlargement >2 centimeters, or increasing hematocrit concurrent with rapid decrease in platelet count should be closely monitored until the risk period is over^{18-21,23}.

There is no specific treatment for dengue fever, but supportive therapy is essential^{18-21,23}. Excessive fluid therapy should be avoided^{18-21,23}. Additionally, non-steroidal anti-inflammatories (NSAIDs) and acetylsalicylic acid (Aspirin) should be avoided as these drugs can exacerbate gastritis and worsen hemorrhagic disease manifestations^{18-21,23}. For patients with signs of shock, hemorrhage, or organ impairment, hospitalization is required^{18-21,23}. Patients should receive fluid replacement for plasma loss to maintain circulation^{20,21,23}. Fluid input and output should be carefully monitored^{20,21,23}. Discharge criteria include no fever for 48 hours, clinical improvement (appetite and general wellbeing), increasing platelet counts, and stable hematocrit levels without intravenous fluids^{18-21,23}. For more specific information, please see the WHO Dengue Guidelines for Diagnosis, Treatment, Prevention, and Control²⁰.

Dengue Laboratory Testing

Laboratories

The Arizona State Public Health Laboratory (ASPHL) can perform PCR and IgM ELISA antibody testing for dengue virus¹⁴. This testing does not determine the serotype. Several commercial laboratories also perform dengue diagnostic testing. Additional testing can be performed at the CDC Dengue Branch laboratory, located in San Juan, Puerto Rico²⁴. In general, samples should first be tested at a commercial lab, and then forwarded to the Arizona State Public Health Laboratory (ASPHL) for confirmatory testing.

Samples

Dengue virus is most commonly detected in blood, serum, or plasma, but tissues from affected organs can also be tested in severe or postmortem cases^{20,21}. The following time periods after disease onset can be used to guide test selection.

- **0–3 days: RT-PCR**^{4,20,21,23}
- **4–6 days: both RT-PCR and IgM**^{4,20,21,23}
- **≥7 days: IgM**^{4,20,21,23}

For patients with negative acute IgM results, and no PCR testing performed, convalescent phase serum should be collected 10–14 days after the first sample to identify a four-fold change in antibody titer or to definitively rule out the diagnosis^{20,21}. Also, a single convalescent titer is sufficient for a probable case classification if no acute-phase

specimen was collected^{17,25}. IgM antibodies can persist for months after illness. A table of additional diagnostic method options is found below.

| Diagnostic Method | Specimen | Collection After Symptom Onset | Laboratory Classification |
|---|--|---|--|
| Viral isolation by cell culture ^{17,20,25} | Whole blood, serum, plasma, CSF, tissues ^{17,20,25} | 1–5 days ^{17,20,25} | Confirmed ^{17,20,25} |
| Nucleic acid detection by RT-PCR or another molecular diagnostic test ^{17,20,25} | Whole blood, plasma, serum, tissues, CSF ^{17,20,25} | 1–5 days ^{17,20,25} | Confirmed ^{17,20,25} |
| NS1 antigen detection by immunoassay ^{17,20,25} | Serum or plasma ^{17,20,25} | 1–6 days ^{17,20,25} | Confirmed ^{17,20,25} |
| Antigen detection by immunofluorescence or immunohistochemistry ^{17,20,25} | Tissue ^{17,20,25} | N/A ^{17,20,25} | Confirmed ^{17,20,25} |
| IgM anti-DENV by validated immunoassay ^{17,20,25} | Serum, plasma, whole blood, CSF ^{17,20,25} | >3 days ^{17,20,25} | Probable ^{17,20,25} |
| IgG anti-DENV by validated immunoassay (paired sera) ^{17,20,25} | Serum, plasma, whole blood ^{17,20,25} | 1–5 days and >15 days ^{17,20,25} | Confirmed if >4-fold rise in titer ^{17,20,25} |

Specimen Collection, Storage and Transportation

1. Collect 4-5 ml of blood aseptically in a tube or a vial^{14,24}.
 - a. Any serum vial is appropriate, including red top, orange top or tiger top tubes^{14,24}.
2. Allow blood to clot at room temperature^{14,24}.
3. Centrifuge at 2,000 rpm to separate serum, and then collect the serum in a clean dry vial^{14,24}.
4. Transport samples at 2–8 °C (NOT frozen, as hemolysis can interfere with serological testing)^{14,24}.
 - a. If specimens are frozen, virus isolation and molecular diagnosis are still possible^{14,24}.
 - b. If a delay of >24 hours is expected, the specimen should be separated and stored at a refrigerated temperature^{14,24}.

Additional Testing

Diagnostic testing for dengue is necessary because of the non-specific signs and symptoms, and range of disease manifestations^{20,21,23}. Antibody tests for dengue can cross-react with other flaviviruses, including West Nile virus, St. Louis encephalitis and Japanese encephalitis^{14,20,21,23}. If the case is suspected to be locally acquired, West Nile virus and St. Louis encephalitis virus should be ruled out through comparison of plaque reduction neutralization (PRNT) test results¹⁴. RT-PCR can also be used for a confirmatory diagnosis if the specimen is collected early in the course of illness. If the case is travel-associated, other pathogens from the region where exposure occurred should be considered.

Dengue Case Definitions

The Council for State and Territorial Epidemiologists (CSTE) released new case definitions for dengue in early 2026²⁵. Clinical presentation is divided into dengue and severe dengue (dengue-like illness used previously has been removed from the 2026 case definition). Case classifications as confirmed and probable are based on the laboratory results and epidemiologic criteria.

2026 Dengue Case Definition

Please also refer to the [ADHS Case Definition Manual](#).

Clinical Description

Clinical evidence of **dengue** includes fever or chills as reported by the patient or healthcare provider* AND the presence of one or more of the following manifestations:

- Nausea or vomiting, which may be persistent (e.g., ≥ 3 episodes in 1 hour or ≥ 4 episodes in 6 hours)
- Rash
- Aches and pains (headache, retro-orbital pain, arthralgia [joint pain], myalgia [muscle aches])
- Positive tourniquet test
- Thrombocytopenia (e.g., platelet count $< 150,000/\text{mm}^3$)
- Leukopenia (e.g., a total white blood cell count of $< 5,000/\text{mm}^3$)
- Any warning sign for severe dengue:
 - Abdominal pain or tenderness
 - Extravascular fluid accumulation (e.g., pleural or pericardial effusion, ascites) without respiratory distress
 - Mucosal bleeding** (e.g., gums, nose [epistaxis], vagina [menorrhagia], kidney [macroscopic hematuria] or mild GI bleeding)
 - Liver enlargement > 2 centimeters
 - Increasing hematocrit ($> 20\%$ in 2 measurements taken 6 hours apart).

* The vast majority of dengue cases are characterized by fever or chills. If fever or chills are not present, or are the only symptoms present, or cannot be ascertained, a patient can still be considered clinically compatible after careful consideration of the patient's clinical course, exposure history, and environmental risk. Visit <https://www.cdc.gov/dengue/areas-with-risk/index.html> for geographic areas with known current or previous risk of DENV.

** If bleeding is severe (see below), consider severe dengue.

Severe dengue is characterized by any one or more of the following scenarios:

- Severe bleeding defined as one or more of the following:
 - Bleeding (most commonly gastrointestinal, e.g., hematemesis, melena) that results in hemodynamic instability or blood transfusion (except platelets), OR
 - Bleeding that results in permanent disability (e.g., CNS bleed or intraocular bleed), OR
 - Bleeding classified as severe by a clinical provider.
- Severe plasma leakage evidenced by shock or extravascular fluid accumulation (e.g., pleural or pericardial effusion, ascites) AND respiratory distress. A high hematocrit value for patient age and sex offers further evidence of plasma leakage.
- Severe organ involvement, including any of the following:

- Elevated liver transaminases: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1,000 units per liter (U/L), OR
- Impaired level of consciousness and/or diagnosis of encephalitis, encephalopathy, or meningitis, OR
- Heart or other organ involvement including myocarditis, cholecystitis, and pancreatitis.

Laboratory Criteria for Surveillance

Confirmatory laboratory evidence

- Detection of dengue virus (e.g., growth in cell culture), viral antigen (e.g., NS1 antigen-capture ELISA, immunohistochemistry), or viral RNA (e.g., PCR) in a serum, plasma, blood, cerebral spinal fluid (CSF), other body fluid, or tissue specimen, OR
- Detection of anti-DENV IgM antibodies in a serum or CSF specimen AND
 - Detectable DENV-specific neutralizing antibody titers by plaque reduction neutralization (PRNT)¹, AND
 - Negative neutralizing antibody titers against other flaviviruses endemic to the region where exposure occurred.

Presumptive laboratory evidence

- Detection of anti-DENV IgM antibodies in a serum specimen², OR
- Demonstration of a ≥ 4 -fold rise in DENV-specific neutralizing antibody titers in paired serum samples optimally collected ≥ 2 weeks apart with a ≥ 4 -fold higher end point titer as compared to other flaviviruses tested³.

¹ Anti-DENV IgM antibody assays do not measure neutralizing antibodies. Neutralizing antibodies are the ones measured by PRNT. Dengue neutralizing antibodies can persist for many years following a symptomatic or asymptomatic infection. A high proportion of people living in dengue-endemic areas have experienced a previous dengue infection; the presence of neutralizing antibodies alone is only evidence of previous infection. In a single sample, PRNTs can help rule out other flaviviruses but cannot differentiate between recent and remote (unrelated to the current illness) infection from DENV among people with previous exposure. For this reason, negative neutralizing antibody titers against other endemic flaviviruses are needed to confirm the case.

² In the setting of an outbreak or known transmission of another flavivirus (e.g., Zika or WNV), obtaining negative IgM results for the other flaviviruses is recommended. If IgM antibodies from other flaviviruses are detected and neutralizing antibodies are unable to differentiate flaviviruses, consider reporting the case as 'Unspecified Flavivirus.'

³ During a second flavivirus infection, cross-reactive antibodies from the first infecting dengue virus serotype or flavivirus (the "original antigen") can predominate over the current infecting flavivirus. Neutralizing antibody results should be interpreted with caution when previous dengue infection is suspected or when titers are high against multiple dengue virus serotypes or flaviviruses.

Case Classification

Confirmed

- Meets clinical criteria AND confirmatory laboratory evidence.

Probable

- Meets clinical criteria AND presumptive laboratory evidence.

Criteria to Distinguish a New Case from an Existing Case


DENV infection results in long-lasting immunity to symptomatic dengue infection with that DENV-type. However, cross-protective (heterotypic) immunity against DENV infection is short-lived, with estimated durations of 1–3 years. In DENV endemic areas where infection pressure is high, individuals have been shown to infrequently have sequential episodes of dengue with two different infecting serotypes. Additionally, detectable IgM anti-DENV can persist for approximately 90 days.

- A person with two clinical episodes of dengue **occurring at least two weeks apart** and shown to be **due to different infecting serotypes** confirmed by molecular diagnostic testing would be counted as **two different cases**.OR

In the absence of molecular testing evidence showing infection due to different infecting serotypes, a person with **two clinical episodes of dengue occurring more than 90 days apart would be counted as two different cases**.

To assist in classifying a potential dengue case, a case classification algorithm is found below.

Dengue Case Classification Algorithm



Dengue Case Classification Algorithm Notes

* **Neutralizing antibodies** are the ones measured by **PRNT**. Dengue neutralizing antibodies can persist for many years following infection; the presence of neutralizing antibodies alone is only evidence of previous infection.

** In a single sample, PRNTs can help rule out other flaviviruses but **cannot differentiate between recent and remote** (unrelated to the current illness) **infection** from DENV among people with previous exposure. For this reason, negative neutralizing antibody titers against other endemic flaviviruses are needed to confirm the case.

^ In the setting of an outbreak or known transmission of another flavivirus (e.g., Zika or WNV), **obtaining negative IgM results for the other flaviviruses is recommended**. If IgM antibodies from other flaviviruses are detected and neutralizing antibodies are unable to differentiate flaviviruses, consider reporting the case as ‘Unspecified Flavivirus Group 1 (WNV/SLE)’ or ‘Unspecified Flavivirus Group 2 (DEN/ZKA)’.

^^ **During a second flavivirus infection**, cross-reactive antibodies from the first infecting dengue virus serotype or flavivirus (the “original antigen”) can predominate over the current infecting flavivirus. Neutralizing antibody results should be **interpreted with caution** when previous dengue infection is suspected or when titers are high against multiple dengue virus serotypes or flaviviruses (see example in [Lanciotti RS et al. EID 2008](#)).

Dengue Lab Result and Classification Examples

CONFIRMED DENGUE CASE EXAMPLE:

- DEN IgM positive

PRNT Results:

- DENV-1 1: 80
- DENV-2 1: 20
- DENV-3 1: 80
- DENV-4 <1:10 (negative)
- SLEV <1:10 (negative)
- WNV <1:10 (negative)

1. IgM positive? Yes
2. Detectable PRNT? Yes
3. Negative PRNT for other endemic flaviv? Yes

CONFIRMED DENGUE CASE (if clinically compatible)

Dengue serotype not determined as no single titer is 4 x higher.

PROBABLE DENGUE CASE EXAMPLE:

- DEN IgM positive

PRNT Results:

- DENV-1 1: 10,204
- DENV-2 1: 640
- DENV-3 1: 2,560
- DENV-4 1: 160
- SLEV 1:10
- WNV <1:10 (negative)

1. IgM positive? Yes
2. Detectable PRNT? Yes
3. Negative PRNT for other endemic flaviv? No (SLE is positive)

PROBABLE DENGUE CASE (if clinically compatible)

Serotype should be interpreted with caution for presumptive testing as previous flavivirus exposure can lead to high PRNT titers.

For more information, please refer to the [ADHS Case Definitions for Communicable Morbidities Manual](#)

Dengue Lab Result and Classification Examples

PROBABLE DENGUE CASE EXAMPLE

DENV IgM negative or not done

PRNT results on acute sample:

- DENV-1 **1:320**
- DENV-2 1:160
- DENV-3 1:80
- DENV-4 1:80
- SLE <1:10 (negative)
- WNV <1:10 (negative)

PRNT results on convalescent sample:

- DENV-1 **1:1,280**
- DENV-2 1:320
- DENV-3 1:80
- DENV-4 1:320
- SLEV <1:10 (negative)
- WNV **1:160**

1. IgM positive? No
2. Detectable PRNT? Yes
3. Paired and acute samples tested by PRNT? Yes
4. >= 4-fold rise in DENV-specific neutralizing antibody titers by PRNT? Yes (from 1:320 to 1:1,280 for DENV-1)
5. >= 4-fold higher end point titer by PRNT as compared to other (non-dengue) flaviviruses tested? Yes (1,280 is 4x higher than the WNV and SLE titers of 1:160 and <1:10)

PROBABLE DENGUE CASE (if clinically compatible)

NOT A DENGUE CASE EXAMPLE

DENV IgM negative or not done

PRNT results on acute sample:


- DENV-1 **1:320**
- DENV-2 1:160
- DENV-3 1:80
- DENV-4 1:80
- SLE <1:10 (negative)
- WNV <1:10 (negative)

PRNT results on convalescent sample:

- DENV-1 **1:1,280**
- DENV-2 1:320
- DENV-3 1:80
- DENV-4 1:320
- SLEV <1:10 (negative)
- WNV **1:640**

1. IgM positive? No
2. Detectable PRNT? Yes
3. Paired and acute samples tested by PRNT? Yes
4. >= 4-fold rise in DENV-specific neutralizing antibody titers by PRNT? Yes (from 1:320 to 1:1,280 for DENV-1)
5. >= 4-fold higher end point titer by PRNT as compared to other (non-dengue) flaviviruses tested? No (1,280 is not 4x higher than the WNV titer of 1:640)

NOT A DENGUE CASE




III: ZIKA

Due to the nature of the rapidly evolving Zika outbreak in the Americas, information in this document is draft and subject to change. Please visit cdc.gov/zika or azhealth.gov/zika for updated guidance.

Zika virus is a single-stranded RNA virus of the *Flaviviridae* family that is primarily spread through the bite of an infected *Aedes* species mosquito²⁶. The virus was first identified in 1947 from a Rhesus monkey in Uganda; however, the first outbreak in the Americas occurred in early 2015, when the virus was found in northeastern Brazil^{26,27}. By the end of

2016, Zika had spread to 75 countries and territories in Central America, South America, the Caribbean, and parts of African and Southeast Asia²⁸. Isolated local transmission was also reported in Florida and Texas during 2016²⁹. For more information about areas with Zika transmission, please see [CDC's webpage](#) or the [PAHO/WHO Zika webpage](#).

World Map of Areas with Risk of Zika



Zika in Arizona

The presence of Zika virus in the Americas greatly increases the likelihood for imported cases of Zika virus in Arizona. Local transmission of Zika virus from mosquitoes is possible due to abundant populations of *Ae. aegypti* in many parts of the state¹⁰. However, imported cases of chikungunya and dengue virus in recent years have not led to local transmission of disease, and the probability of widespread locally acquired mosquito-borne disease is likely low^{27,31,32}. Travelers and residents are reminded to avoid mosquitoes both when traveling and in Arizona to reduce the risk of travel-associated disease from chikungunya, dengue, or Zika, as well mosquito-borne diseases in the state such as West Nile virus and St. Louis encephalitis virus^{26,29,33}. An epidemiological profile of Zika cases in Arizona from 2008 through 2016 is available in the Appendix.

Unlike chikungunya and dengue viruses, Zika transmission through sexual contact or congenital or perinatal infection is also a concern^{26,27}. Limited transmission in Arizona through these mechanisms is possible. To decrease this risk, pregnant women should avoid travel to [Zika-affected areas](#) during pregnancy, and women and men who are planning to conceive in the near future should consider avoiding nonessential travel to areas with risk of Zika.^{26,27}. In addition, pregnant women and individuals with pregnant partners should

abstain from sexual activity or correctly use condoms during sex with their pregnant partner for the duration of the pregnancy^{26,27}. More information about Zika and pregnancy is available [here](#).

Zika Ecology and Transmission

Reservoirs

Zika virus has been shown to infect and cause disease in humans and non-human primates³⁴. Antibodies have also been detected in a variety of organisms, including rodents, birds, sheep, goats, cattle, horses, bats, ducks, and reptiles^{34,35}.

However, humans are believed to have become the prominent host for the Asian lineage of Zika virus, and transmission can be sustained in a human-endemic cycle³⁵.

Incubation period

- **Humans: 3-14 days** between the bite of an infected mosquito and when symptoms begin (intrinsic incubation)²⁶.
- **Mosquitoes: ~10 days** between intake of a Zika- infected blood meal and when mosquitoes can transmit the virus to a naïve human host (extrinsic incubation)³⁶.

Zika Virus Strains

Two major lineages of Zika virus have been identified — the Asian strain and the African strain³⁵. The 2015-2016 Zika virus outbreak in the Americas was identified as the Asian strain³⁵.

Zika Clinical Disease and Case Management

The most common symptoms of Zika infection include acute onset of fever, maculopapular rash, arthralgia, and nonpurulent conjunctivitis, as well as myalgia and headache; however, nearly 80% of infected patients are asymptomatic^{26,27}. If symptoms occur, they are thought to occur 2-12 days after the bite of an infected mosquito and can last up to a week^{26,27}. Hospitalization is rarely required, and death from Zika complications is a rare occurrence^{26,27}. Current research suggests that Guillain-Barré syndrome (GBS) is associated with Zika virus infection; however, only a small proportion of infected individuals will develop GBS^{26,27}.

Testing for Zika virus should be considered among patients who traveled to or had unprotected sexual contact with someone who traveled to an area with Zika virus and have experienced symptoms of Zika virus infection^{26,27}. Asymptomatic pregnant women should be tested for if there is ongoing exposure to Zika virus^{26,27}. Healthcare providers should contact the [local health department](#) to report suspect cases and coordinate

testing at a public health laboratory, if needed. More information about specimen collection, handling, and shipping for Zika virus is available [here](#)¹⁴.

Many other diseases can have a similar clinical presentation as Zika virus²⁶. Dengue, chikungunya, leptospirosis, malaria, rickettsia, group A streptococcus, rubella, measles, parvovirus, enterovirus, adenovirus, and other pathogens should be considered in persons with suspected Zika infection²⁶.

Currently, there is no vaccine or specific treatment for Zika virus infection^{26,27}. Patients can be treated with supportive care; nonsteroidal anti-inflammatories (NSAIDs) and acetylsalicylic acid (Aspirin) should be avoided until dengue is ruled out^{26,27}. Persons suspected of Zika infection should be advised to prevent mosquito bites to stop disease transmission.

Congenital Zika Virus Syndrome

In 2015, a temporal and geographic association with a large Zika virus outbreak in Brazil and an increase in microcephaly cases in infants was identified²⁶. After a rigorous evaluation of the scientific evidence, the CDC and international partners have concluded that Zika virus infection during pregnancy is a cause of microcephaly and other severe birth defects^{26,27,37}. Zika virus infection during pregnancy can cause a pattern of birth defects, called Congenital Zika virus syndrome^{26,27}. Congenital Zika virus syndrome can include microcephaly, decreased brain tissue, damage to the eye, limited range of joint motion, and too much muscle tone restricting body movement after birth^{26,27}. There is currently no evidence to suggest that a Zika infection in a non-pregnant woman can affect future pregnancies^{26,27}.

Zika Laboratory Testing

***Note: Testing algorithms are available online at:**

<http://www.azdhs.gov/preparedness/epidemiology-disease-control/mosquito-borne/index.php#zika-info-for-providers>.

Laboratories

The Arizona State Public Health Laboratory (ASPHL) can perform RT-PCR, and plaque reduction neutralization testing (PRNT) for Zika virus¹⁴. For Zika virus testing, serum must be submitted¹⁴. Within two weeks of exposure, urine and whole blood can also be tested¹⁴. For more information about Zika specimen handling and shipment, please see the [ADHS Zika laboratory webpage](#)¹⁴.

Samples

Serum is the primary diagnostic specimen for Zika virus testing¹⁴. For pregnant individuals, RT-PCR should be run as soon as possible after symptom onset, up to 12 weeks after onset^{26,27}. Additional specimens—including cerebrospinal fluid, amniotic fluid, and placental tissues—can be tested in consultation with the local health department, Arizona Department of Health Services, and CDC^{14,26}.

Updated Zika Testing Guidelines (2019)

The last positive nucleic acid amplification test (NAAT) confirming a locally acquired infection was in 2017, and the last positive NAAT confirming a locally acquired infection in the US territories was in 2018. As of 2019, there are currently outbreaks of Dengue virus in areas outside of the US that previously had high numbers of Zika cases, that now have low to no Zika virus transmission. Therefore, it is recommended that testing for both viruses be performed after traveling from these areas. Non-pregnant symptomatic patients are no longer recommended to be tested for Zika and should instead follow testing guidelines for dengue.

Testing for Zika is currently only recommended for **symptomatic pregnant women who had recent travel to areas of risk of Zika** (any non green areas on the CDC map <https://wwwnc.cdc.gov/travel/page/zika-information>).

- Dengue and Zika virus NAAT should be performed as soon as possible but up to 12 weeks after the onset of symptoms.
- Dengue and Zika virus NAAT on a serum specimen or dengue NAAT on serum with Zika virus NAAT on a urine specimen should be performed at the same time.
- IgM testing should only be performed for dengue.
 - Zika IgM antibodies may persist for months to years and therefore do not indicate a recent infection.
 - There may also be cross-reactivity between dengue and Zika, and a recent dengue infection may cause a false positive Zika IgM result.
- If a Zika NAAT is positive on a single specimen, it should be repeated on newly extracted RNA from the same specimen to rule out a false positive.
- If the dengue NAAT (concurrently tested with a Zika NAAT) is positive, this is adequate evidence of a dengue infection and further testing is not warranted.

For symptomatic pregnant women who have had sex with someone who lives in or has recently traveled to areas of risk of Zika (dark purple area on the CDC map: <https://wwwnc.cdc.gov/travel/page/zika-information>):

- Only Zika NAAT should be performed within the same time frame.

- If positive, it should be repeated on newly extracted RNA from the same specimen to rule out a false-positive NAAT.

Pregnant women with fetal ultrasound findings consistent with a congenital Zika virus infection who lived in or traveled to areas with a risk of Zika during pregnancy:

- Zika NAAT and IgM should be performed on maternal serum and NAAT on maternal urine.
- If the NAAT is negative but IgM is positive, confirmatory PRNTs should be performed against Zika and dengue.
- If amniocentesis is performed as part of clinical care, a NAAT should be performed on amniocentesis specimens with results interpreted within the context of limitations of amniotic fluid testing. The sensitivity and specificity of RNA NAAT on amniotic fluid for congenital Zika is not known, nor does this help determine the likelihood of an infant being born with abnormalities.
- Testing of placental and fetal tissues may also be performed following CDC guidelines for submitting specimens at the time of birth.
 - <https://www.cdc.gov/zika/hc-providers/test-specimens-at-time-of-birth.html>

<https://www.cdc.gov/zika/hc-providers/testing-guidance.html>

Continued Zika Surveillance in Arizona

If a locally acquired Zika virus infection is suspected, trapping of mosquitoes on and near the suspected area of transmission can help to identify positive vectors, which can greatly decrease the chances of a possible outbreak. VectorSurv <https://vectorsurv.org/> is an online surveillance program that can be used by local and county health departments when performing surveillance. Once trapped mosquito species are tentatively identified, this data can be entered into the program which can then be uploaded to CDC's surveillance program, ArboNet. If a local or county health department has obtained *Aedes aegypti* mosquitoes from an area with a possible case, these mosquitoes can also be submitted to the Arizona State Department of Health Services for testing to identify any positive vectors.

Additional Testing

When testing symptomatic patients for Zika virus, testing for dengue and chikungunya viruses should also be considered²⁶. All three infections have similar clinical manifestations, and testing can help identify the causative agent²⁶.

If Zika testing is being performed as part of a workup for an infant with microcephaly, diagnostic testing for other causes of microcephaly should also be performed^{26,27}.

Zika Case Definitions

The Council for State and Territorial Epidemiologists (CSTE) released draft case definitions for Zika virus in early 2016, and approved revised case definitions in June 2016³⁸. In 2024 the case definition was further update with the removal of Zika virus non-congenital and congenital infection without disease subtypes from the case definition and list of Nationally Notifiable Conditions and revisions to the epidemiologic linkage criteria for case classification to provide more specificity on the timing of exposure (among other changes). Refer to the 2024 case definition below and to the [ADHS Case Definition Manual](#).

Clinical Criteria

A clinically compatible case of Zika Virus Disease is defined as follows:

Non-Congenital Zika Virus Disease:

A person with one or more of the following not explained by another etiology:

- Clinically compatible illness that includes:
 - Acute onset of fever (measured or reported); **OR**
 - Generalized rash; **OR**
 - Arthralgia; **OR**
 - Non-purulent conjunctivitis
- Complication or pregnancy
 - Fetal loss (at ≥ 20 weeks of gestation)
- Guillain-Barré syndrome

Congenital Zika Virus Disease:¹

To meet the clinical criteria for congenital Zika virus disease, the liveborn infant must not have an identified genetic or other cause for the findings, including a positive test for another likely etiology*, and should have one or more of the following brain or eye anomalies or neurological sequelae specific for congenital Zika virus disease and typically identifiable in the neonatal period:

- Microcephaly (occipital frontal circumference >2 standard deviations below the mean for age and sex) at birth or postnatal onset,
- Cortical hypoplasia or abnormal gyral patterns (polymicrogyria, lissencephaly, heterotopia),
- Increased volume of cerebrospinal fluid (CSF) (hydrocephalus ex vacuo, unspecified hydrocephalus, ventriculomegaly) due to loss of brain parenchyma,
- Intracranial calcifications (most commonly between the cortex and subcortex),

- congenital contractures of major joints (arthrogryposis) associated with structural brain anomalies,
- Congenital paralysis of the diaphragm associated with structural brain anomalies,
- Corpus callosum agenesis/hypoplasia,
- Cerebellar hypoplasia,
- Scarring of the macula with coarse deposits of pigment in the retina (focal retinal pigmentary mottling),
- Other structural eye anomalies (microphthalmia, cataracts, chorioretinal atrophy, optic nerve hypoplasia).

¹Clinical findings can be observed during prenatal or postnatal evaluations. Consult with CDC as needed for assistance with congenital Zika virus disease clinical determinations.

* Other clinical considerations for congenital Zika virus disease: among congenital infections, cytomegalovirus infection has clinical findings most consistent with Zika virus infection and should be ruled out by diagnostic testing. While other infectious etiologies (e.g., rubella virus, varicella zoster virus, herpes simplex virus, lymphocytic choriomeningitis virus, *Toxoplasma gondii*, or *Treponema pallidum*) have clinical findings less consistent with congenital Zika virus disease, testing for these infections should be considered as part of the complete evaluation for congenital disease.

Laboratory Criteria

Non-Congenital Zika Virus Disease:

Confirmatory laboratory evidence

- Detection of Zika virus, viral antigen, or viral RNA in a body fluid or tissue; **OR**
- Detection of anti-Zika virus IgM antibodies in blood or CSF, with positive Zika virus-specific neutralizing antibody titers and negative neutralizing antibody titers against dengue or other flaviviruses endemic to the region where exposure occurred².

Presumptive laboratory evidence

- Detection of anti-Zika virus IgM antibodies in blood or CSF with a negative anti-dengue virus IgM antibody test in the same specimen with no neutralizing antibody testing performed; **OR**
- Four-fold or greater rise in anti-Zika virus-specific neutralizing antibody titers in paired blood specimens; **OR**
- In the setting of a Zika virus outbreak³ with minimal circulation of other endemic flaviviruses, detection of anti-Zika virus IgM antibodies in blood or CSF.

Congenital Zika Virus Disease:

Confirmatory laboratory evidence

- Detection of Zika virus, viral antigen, or viral RNA in infant CSF, blood, urine, or postmortem tissue^{**}; **OR**
- Detection of anti-Zika virus IgM antibodies in infant CSF or blood^{**}, with positive anti-Zika virus-specific neutralizing antibody titers.

Presumptive laboratory evidence

- Detection of Zika virus, viral antigen, or viral RNA in amniotic fluid, placenta, umbilical cord, or cord blood**; **OR**
- Detection of anti-Zika virus IgM antibodies in infant CSF or blood** with no neutralizing antibody testing performed.

**To prevent misclassifying postnatal Zika virus infections as congenital cases, in Zika virus endemic areas specimens should be collected within 4 weeks after birth.

² If Zika and dengue virus IgM antibodies are detected and neutralizing antibodies are unable to differentiate flaviviruses, consider reporting as Flavivirus disease, not otherwise specified (See ArboNET Surveillance).

³ Consult with CDC as needed for assistance with outbreak status determinations.

Epidemiologic Linkage

- Residence in or recent travel to an area with known local Zika virus transmission in the 14 days before the onset of symptoms, in the 28 days before the onset of Guillain-Barré syndrome, or during pregnancy (consult with CDC for assistance with geographic risk determination); **OR**
- Laboratory exposure to Zika virus before onset of symptoms or during pregnancy; **OR**
- Sexual contact, within 14 days of symptom onset or during pregnancy, with a person who in the last 90 days has either been diagnosed with Zika virus infection or has returned from traveling to an area with a risk of Zika virus transmission; **OR**
- Receipt of blood, blood products, organ transplant, or tissue transplant within 30 days of symptom onset or during pregnancy from a person who has either been diagnosed with Zika virus infection or returned from traveling to an area with risk of Zika virus transmission.

Case Classification:

Non-Congenital Zika Virus Disease:

Confirmed

- Meets the epidemiologic linkage criteria, and clinical and confirmatory laboratory criteria for non-congenital Zika virus disease.

Probable

- Meets the epidemiologic linkage criteria, and clinical and presumptive laboratory criteria for non-congenital Zika virus disease.

Congenital Zika Virus Disease:

Confirmed


- Meets the clinical criteria for congenital Zika virus disease; **AND**
- Meets confirmatory laboratory criteria for congenital Zika virus disease; **AND**
- Whose gestational parent meets:
 - epidemiologic linkage criteria; **OR**
 - confirmatory laboratory criteria for non-congenital Zika virus disease during this pregnancy.

Probable


- Meets the clinical criteria for congenital Zika virus disease; **AND**
- Meets presumptive laboratory criteria for congenital Zika virus disease; **AND**
- Whose gestational parent meets:
 - epidemiologic linkage criteria; **OR**
 - confirmatory laboratory criteria for non-congenital Zika virus disease during this pregnancy.

Zika Virus Case Classification Algorithm

Congenital vs Non-Congenital Zika Algorithm



Zika Virus Case Classification Algorithm



Clinically Compatible Illness


Does the individual have one or more of the following, not explain by another etiology:

- Clinically compatible illness that includes:
 - Acute onset of fever (measures or reported) OR
 - Maculopapular rash OR
 - Arthralgia OR
 - Conjunctivitis;
- Complication of pregnancy
 - Fetal loss OR
 - Fetus or neonate with
 - Congenital microcephaly OR
 - Congenital intracranial calcifications OR
 - Other structural brain or eye abnormalities;
- Guillain-Barré syndrome or other neurologic manifestations

Epidemiologic Linkage

- Resides in or recent travel to an area with known local Zika virus transmission OR
- Sexual contact with a confirmed or probable case within the infection transmission risk window of Zika virus infection or person with recent travel to an area with known Zika virus transmission OR
- Receipt of blood or blood products within 30 days of symptom onset OR
- Organ or tissue transplant recipient within 30 days of symptom onset OR
- Association in time and place with a confirmed or probable case OR
- Likely vector exposure in an area with suitable seasonal and ecological conditions for potential local vector-borne transmission

Zika Virus Case Classification Algorithm



Clinically Compatible Illness

Is the individual a live-born infant with one or more of the following not explained by another etiology:

- Congenital microcephaly OR
- Intracranial calcifications OR
- Structural brain or eye abnormalities OR
- Other congenital central nervous system-related abnormalities

Note: testing for other congenital infections such as syphilis, toxoplasmosis, rubella, cytomegalovirus infection, lymphocytic choriomeningitis infection, and herpes simplex virus infection should be considered in addition to an assessment of potential genetic and teratogenic causes of congenital anomalies.

Epidemiologic Linkage

- Resides in or recent travel to an area with known local Zika virus transmission OR
- Sexual contact with a confirmed or probable case within the infection transmission risk window of Zika virus infection or person with recent travel to an area with known Zika virus transmission OR
- Receipt of blood or blood products within 30 days of symptom onset OR
- Organ or tissue transplant recipient within 30 days of symptom onset OR
- Association in time and place with a confirmed or probable case OR
- Likely vector exposure in an area with suitable seasonal and ecological conditions for potential local vector-borne transmission

IV. CHIKUNGUNYA, DENGUE, AND ZIKA COMPARISON

Dengue, chikungunya, or Zika virus infection can lead to acute febrile illness, and determining the causative virus can be challenging to differentiate clinically. The information in this section is intended to assist in differential diagnosis of these diseases.

Comparison of the clinical and laboratory features of chikungunya, dengue, and Zika virus infections^{6,39}

| Clinical and laboratory features ^{6,39} | Chikungunya virus infection ^{6,39} | Dengue virus infection ^{6,39} | Zika virus infection ^{6,39} |
|--|---|--|--------------------------------------|
| Fever (>102°F or 39°C) ^{6,39} | +++ | +++ | ++ |
| Myalgias ^{6,39} | + | ++ | + |
| Arthralgias ^{6,39} | +++ | + | ++ |
| Headache ^{6,39} | ++ | ++ | + |
| Rash ^{6,39} | ++ | + | +++ |
| Conjunctivitis ^{6,39} | - | - | ++ |
| Hemorrhage ^{6,39} | - | ++ | - |
| Shock ^{6,39} | - | + | - |
| Leukopenia ^{6,39} | ++ | +++ | not available |
| Neutropenia ^{6,39} | + | +++ | not available |
| Lymphopenia ^{6,39} | +++ | ++ | not available |
| Elevated hematocrit ^{6,39} | - | ++ | not available |
| Thrombocytopenia ^{6,39} | + | +++ | not available |

Key points:

- **Chikungunya** cases are more likely to have **high fever, arthralgia, and lymphopenia**^{6,39}.
- **Dengue** cases are more likely to have **leukopenia, neutropenia, and thrombocytopenia**^{6,39}.
- **Zika** cases are more likely to have a **rash and conjunctivitis**^{6,39}.

Differential diagnoses for dengue, chikungunya, and Zika include the following agents or diseases⁴⁰⁻⁴²:

- Malaria
- Rocky Mountain spotted fever
- Leptospirosis

- Other alphaviral infections (Mayaro, Ross River, Barmah Forest, O'nyong nyong, and Sindbis viruses)
- Post-infectious arthritis (including rheumatic fever)
- Juvenile rheumatoid arthritis
- Unknown hemorrhagic fever

| Epidemiology | Chikungunya virus infection | Dengue virus infection | Zika virus infection |
|---|---|--|----------------------------|
| Incubation period in humans | 3–7 (range 1–12) Days ^{1,4,6,12} | 4–7 (range 3–14) days ¹⁸⁻²¹ | 3–14 days ^{26,36} |
| Extrinsic incubation period in mosquitoes | ~10 days ^{1,4,6,12} | 8–12 days ¹⁸⁻²¹ | ~10 days ^{26,36} |
| Duration of acute disease | 7–10 days ^{1,4,6,12} | 7–10 days ¹⁸⁻²¹ | ~1 week ^{26,36} |

Recommendations for Healthcare Providers

1) Consider chikungunya, dengue, and Zika viruses in patients with acute febrile illness, particularly if travel out of the country to areas with high mosquito activity is reported. Compatible symptoms include:

- Fever
- Myalgia
- Arthralgia
- Maculopapular rash
- Conjunctivitis
- Retro-orbital pain
- Headache

Other differentials can include malaria, leptospirosis, influenza, Rocky Mountain spotted fever, and other diseases⁴⁰⁻⁴².

2) If chikungunya, dengue, or Zika is suspected, order tests for ALL THREE diseases. Count the number of days after symptom onset to determine which test types are indicated.

- Test intervals:
 - 0–3 days: PCR only^{4,20,21,23,26,27}
 - 4–6 days: PCR and IgM^{4,20,21,23,26,27}
 - ≥7 days: IgM only^{4,20,21,23,26,27}

Note: Prolonged detection of Zika RNA in serum of pregnant women have been reported; therefore, Zika virus PCR and IgM should be run concurrently as soon as possible after symptom onset, up to 12 weeks, in pregnant women^{26,27}.

- b. Specimen type (note: please check with receiving laboratory to confirm shipping instructions)
 - i. Serum is the primary diagnostic specimen for Zika virus¹⁴.
 - ii. If testing at Arizona State Public Health Laboratory (ASPHL), see [Guide to Laboratory Services](#) manual¹⁴.

3) Notify public health IMMEDIATELY about suspect cases

- a. Cases should be reported to the local health department (preferred) or the Arizona Department of Health Services at 602-364-3676 or vbzd@azdhs.gov
- b. Local health departments should coordinate with ADHS to alert the laboratory of incoming specimens.
- c. Advise suspect cases to avoid mosquitoes for 3 weeks after the onset of symptoms or potential exposure.
 - i. Explanation: viremic patients are at risk for virus transmission to mosquitoes. This can lead to locally-acquired disease and community outbreaks. Patients should also contact public health if other household members develop compatible symptoms.

4) Manage cases as dengue until proven otherwise

- a. Do not prescribe aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids^{20,21,23}.
- b. Do not overload fluids^{20,21,23}.

V: PLANNING AND RESPONSE SCENARIOS

Different actions by public health, healthcare providers, and vector control staff are warranted depending on the epidemiologic scenario. This section describes a brief overview of different response scenarios and which actions should be considered. More detailed recommendations by agency are found in the public health, vector control, and messaging sections.

Scenario 1: Risk for imported cases

This is the baseline status for areas with no chikungunya, dengue, or Zika virus transmission. No locally acquired disease cases have been reported. This could be further characterized into 2 categories: low risk and elevated risk.

- Low Risk:
 - *Aedes aegypti* or *Aedes albopictus* mosquitoes not present in the area
 - Few imported cases of chikungunya, dengue or Zika virus infection
- Elevated Risk:
 - *Aedes aegypti* or *Aedes albopictus* present in area
 - Immunologically naïve population
 - High numbers of imported cases of chikungunya, dengue, or Zika virus infection

Scenario 2: Response to locally acquired cases

This scenario occurs if locally acquired cases of dengue, chikungunya, or Zika are identified. This would most likely begin with focal transmission in households, neighborhoods, or communities, but could spread over broader areas.

- Focal transmission
 - Discrete areas (such as neighborhood) affected
 - Small number of locally acquired cases
- Widespread transmission
 - Multiple areas of communities affected
 - High case numbers reported, with exposure locations unknown

Scenario 3: Recovery

The recovery phase is a time to implement sustainable public health measures and to inform the public about the decreased disease incidence and risk. This phase is initiated following a demonstrated decrease in surveillance results (as determined by vector control data) or human disease cases (as determined by epidemiological data).

Collaboration Between Agencies

Control of vectorborne diseases requires cooperation between many different agencies, including public health, environmental health, and vector control partners. Chikungunya, dengue, and Zika are unique arboviruses for Arizona in that they spread only between humans and mosquitoes. Because of this anthropocentric-cycle, surveillance for human disease cases is an effective method to approximate where the virus is found in the environment. The areas with cases should be considered priorities for enhanced surveillance and potentially for vector control interventions.

Public health, vector control, and health educators should collaborate in development and dissemination of educational materials and outreach to the public. As previously noted, major control factors for *Aedes aegypti* or *Aedes albopictus* mosquitoes are personal protection and elimination of mosquito breeding sites near and around the home, and community education and action is necessary to prevent disease transmission.

Partners to Consider for Chikungunya, Dengue, and Zika Response

- Local health departments
- Local vector control agencies
- Pest abatement districts
- State health department
- Commercial and state laboratories
- Centers for Disease Control and Prevention
 - Dengue Branch
 - Arboviral Diseases Branch
 - Division of Global Migration and Quarantine
- Healthcare providers
- Blood donation centers
- Tribal jurisdictions and Indian Health Service
- First responders in emergency preparedness or law enforcement
- Community leaders
- Media partners
- University partners
- Customs and Border Protection
- Binational partners in Mexico or other neighboring jurisdictions

Recommended Response Activities by Epidemiologic Scenario

The table below indicates key preparedness and response activities to consider for chikungunya, dengue, or Zika virus introduction. Earlier actions should be continued into later stages, but are only listed once for simplicity. **More details about recommended actions are found in the public health, vector control, and messaging sections.**

| Response scenario | Other considerations | Actions |
|-------------------------|---------------------------------|--|
| Risk for imported cases | Low Risk | <ul style="list-style-type: none"> ❖ Prepare messaging for public outreach ❖ Strengthen working relationships between public health and vector control agencies |
| | Elevated Risk | <ul style="list-style-type: none"> ❖ Provide education and outreach to healthcare providers ❖ Ensure rapid laboratory testing available for suspect human cases of chikungunya, dengue, or Zika testing ❖ Raise public awareness about <i>Aedes aegypti</i> mosquitoes |
| | Case Investigation and Response | <ul style="list-style-type: none"> ❖ Investigate cases to determine travel history and where acquisition occurred ❖ Advise ill persons to prevent mosquito bites for 3 weeks after symptom onset or potential exposure to chikungunya, dengue, or Zika viruses ❖ Perform <i>Aedes aegypti</i> trapping around the surrounding neighborhoods of cases ❖ Consider laboratory testing for chikungunya, dengue, or Zika among <i>Aedes aegypti</i> mosquitoes ❖ Inquire about illnesses among other household members (active case finding for locally-acquired cases) ❖ Visit surrounding neighborhoods of cases to look for potential <i>Aedes aegypti</i> breeding locations (i.e. water-holding containers) and perform source reduction ❖ Eliminate breeding sites, use larvicide insecticides, and then consider adulticide treatment around case neighborhoods |

| | | |
|---|--------------------------------|--|
| Response to locally - acquired cases | Focal transmission | <ul style="list-style-type: none"> ❖ Inform public about risk of locally-acquired cases through press releases and social media ❖ Consider door-to-door campaign in affected neighborhood(s) for source reduction and to encourage mosquito avoidance ❖ Increase <i>Ae. aegypti</i> trapping and surveillance in affected areas by using oviposition traps or adult traps ❖ Consider laboratory testing for chikungunya, dengue, or Zika among <i>Aedes aegypti</i> mosquitoes in the area, if not already implemented ❖ Perform active case finding in affected communities, or within 150m of case residences ❖ Perform larvicide and/or adulticide spraying of affected neighborhoods ❖ Consider need for screening or deferring blood donations from affected areas ❖ Analyze human and mosquito surveillance data through mapping ❖ Describe epidemiology of persons affected and possible risk factors ❖ Ensure data is shared with public health, vector control, and healthcare partners |
| | Widespread transmission | <ul style="list-style-type: none"> ❖ Launch widespread media campaign <ul style="list-style-type: none"> ○ Raise awareness about risk from disease from mosquito bites ○ Emphasize importance of source reduction ○ Encourage ill persons to seek care ❖ Consider extensive larvicide applications and ultra-low volume spraying in highly-affected neighborhoods to lower mosquito numbers ❖ Activate medical surge capacity plans for healthcare facilities and laboratories as needed ❖ Ensure blood donations from affected areas are tested or deferred to prevent transfusion-associated disease cases ❖ Prioritize laboratory testing for suspect cases in new areas, or with atypical disease presentations |

| | | |
|-----------------------------|--|---|
| | | <ul style="list-style-type: none"> ❖ Consider utilization of mosquito testing for viruses to determine risk levels and viral presence ❖ Continue mapping of human and mosquito data; focus response resources on most affected areas. ❖ Consider screening in blood banks or among blood donors to avoid disease transmission through blood transfusion. |
| <p>Recov ery</p> | | <ul style="list-style-type: none"> ❖ Consider enhanced surveillance for human cases in high-risk areas ❖ Decrease <i>Aedes aegypti</i> surveillance to baseline levels |

Laboratory Surveillance Guidelines: Response Scenarios^{4,29}

| Epidemiologic scenario | Samples to test |
|--|---|
| <p>Risk for imported cases</p> | <ul style="list-style-type: none"> ❖ All samples from patients exhibiting clinically compatible illness ❖ With new introduction of a virus, extra testing should be done to verify viral presence |
| <p>Response to locally acquired cases</p> | <ul style="list-style-type: none"> ❖ Consider testing mosquitoes near the home of locally acquired cases ❖ If widespread transmission, subset samples from human cases with compatible symptoms, as determined by lab constraints and epidemiological status ❖ Samples from all atypical or severe cases should be tested ❖ Once viral presence has been verified, limited testing can be considered. |

VI: PUBLIC HEALTH SURVEILLANCE AND RESPONSE

Section Overview

- Reporting and Agency Roles
- Surveillance and Investigation Guidelines
 - Goals
 - Surveillance Strategies
 - Case Investigation
 - Outbreak Investigation
 - Preventing Transmission
 - Geographic Information Systems
- Other Planning Considerations
 - Bloodborne Transmission
 - Medical Surge
- Incident Command System
- Response Scenarios

Reporting and Agency Roles

Reporting

Chikungunya, dengue, and Zika virus are nationally reportable diseases through the National Notifiable Disease Surveillance System (NNDSS). All three diseases are unique morbidities in MEDSIS for electronic surveillance within Arizona. In an area with no previous locally acquired cases, even a single locally acquired case is considered an outbreak.

If an outbreak is identified, the cases should be entered in Outbreak Module in MEDSIS. This system facilitates outbreak management and tracking. After completion of the investigation, the outbreak should be closed within 30 days.

Local, State, and Federal Roles

As with other infectious disease investigations, local health departments are the lead agency for responding to disease threats within their jurisdictions. Arizona Department of Health Services (ADHS) can assist counties as needed in case investigation and response, and also plays the lead in coordinating outbreak responses across multiple counties or jurisdictions. CDC Dengue Branch (Puerto Rico) and CDC Arboviral Diseases Branch (Fort Collins, CO) can offer subject matter expertise and additional support.

Surveillance and Investigation Guidelines

Human case surveillance for chikungunya, dengue, or Zika virus infections should include the following goals.

- Track the number and distribution of disease cases
- Track pregnancy and infant outcomes (for Zika)
- Identify circulating virus types
- Identify risk factors for infection
- Monitor case distribution for disease introduction into surrounding areas
- Develop disease prevention strategies
- Assess clinical severity and impact on society
- Feedback of findings to collaborative agencies

Surveillance Strategies

In Arizona, passive case-based surveillance is routine. This system relies on case reporting from clinicians and laboratories to public health.

In the event of a locally acquired case or increased risk for cases, public health officials should consider utilizing enhanced surveillance. This includes **active surveillance**, in which public health officials actively collect disease data from suspect cases, clinicians, or laboratories. For more information about active surveillance at the community level, please see “Household-based Cluster Investigations” section below. **Syndromic surveillance**, which detects syndromes rather than disease etiologies, may be useful for detecting underreported cases and disease trends in a timely manner. Syndromic surveillance for arboviral diseases (chikungunya, dengue, St. Louis encephalitis, and West Nile) has been ongoing in Arizona since 2015; Zika was added to syndromic surveillance in 2016.

Laboratory sentinel surveillance is another form of enhanced surveillance that can be used to gather high-quality, detailed data not captured through passive surveillance. This entails using selected reporting facilities to collect detailed information about cases and disease trends, or perform more specific testing for disease syndromes that could be caused by multiple etiologies (e.g., febrile illnesses). The state can assist local public health authorities in initiating enhanced surveillance if requested.

In 2015, ADHS implemented an enhanced **laboratory surveillance system through laboratory orders** for dengue and chikungunya viruses. Because notification of positive laboratory test results can occur days to weeks after illness onset, and because public health intervention is most valuable in the first few days of illness (the viremic period), this

system involves notification of laboratory orders to public health before final test results are available. Currently, it is in place with several commercial laboratories and healthcare facilities in Arizona. Zika virus was added to the laboratory surveillance in 2016.

Case Investigation

Investigation of suspected cases is an important part of public health activities for chikungunya, dengue, or Zika viruses. A short checklist of overview case investigation goals is listed below.

Checklist for Case Investigation

- Ensure case is entered in MEDSIS
 - Ensure that all of the disease specific observations (DSO) are filled out in MEDSIS
- Interview case to determine where exposure most likely occurred (country and region, if possible) and clinical course
- Attach laboratory results if available
- Attach medical records if available

Outbreak Investigation

To understand outbreak development and trends, case information should be assessed in aggregate. A line list of suspect and confirmed cases is useful for data analysis. MEDSIS extracts can be used to pull up-to-date data on a regular basis; Excel worksheets and other databases (Epi Info or Access) are alternatives, but can prove more challenging for data sharing and updating case information. Case investigation forms are available for [chikungunya](#) and [dengue/Zika](#).

Household-based Cluster Investigations

In the event of local disease transmission or increased numbers of travel-associated cases in a focal area, enhanced surveillance for asymptomatic cases or persons who did not seek healthcare can be valuable in identifying the extent of disease spread and directing vector control actions. The cluster investigations are usually focused around confirmed case residences (150m radius) or neighborhoods, and involve interviews, education, and testing of other persons at risk for disease in the area. These also provide an opportunity to identify mosquito breeding sites and take vector control actions (larvicide or adulticide) in high risk zones. Team members needed include interviewers, phlebotomists, and vector control specialists. Additional details, form templates, and supply information for cluster investigations are available from ADHS (by request) and CDC⁴³.

Preventing Transmission

Stopping the spread of chikungunya, dengue, or Zika is challenging because there are currently no approved vaccines available to prevent disease. There are, however, several opportunities for how transmission chain can be stopped. These opportunities and associated prevention actions listed in the following table.

| Opportunities | Potential actions |
|--|---|
| Prevent introduction of human illness | <ul style="list-style-type: none"> ❖ Provide information to travelers about disease risk and prevention while traveling ❖ Ensure viremic persons are not bitten by mosquitoes ❖ Educate travelers about the risk for sexual transmission |
| Reduce or eliminate the competent vector population | <ul style="list-style-type: none"> ❖ Eliminate containers used for breeding (source reduction) ❖ Use larvicide on immature mosquitoes ❖ Use adulticide for adult mosquitoes |
| Limit contact between humans and mosquitoes | <ul style="list-style-type: none"> ❖ Prevent mosquito entry into households (screens in windows or air conditioning) ❖ Prevent mosquito bites by using insect repellent and wearing loose-fitting, long-sleeved shirts and pants |

Geographic Information Systems

Geographic Information Systems (GIS) are an extremely useful tool for providing operational direction and analysis during an outbreak. Several programs are available for mapping, and include ESRI Arc GIS, QGIS, and others. Maps can be created to indicate disease incidence, spatially monitor the outbreak, and track changes in human disease and vector surveillance data as a response to vector control efforts.

Ideally, the baseline vector data as well as the human case data from imported cases will have been mapped prior to the start of the outbreak. This allows for a more accurate comparison of disease incidence across time and space.

Other Planning Considerations

Bloodborne Transmission

Bloodborne disease transmission of chikungunya, dengue, and Zika is possible; this should be considered both at the hospital level for potential needle-sticks, as well as for screening of blood donors if local transmission occurs. Currently, blood donors are not screened for chikungunya or dengue. FDA released guidance recommending testing all donations in the U.S. for Zika virus in August 2016⁴⁴. If local disease transmission is identified, blood donation centers should be contacted immediately to discuss the need for deferral of blood donors from affected areas.

Medical Surge

In the event of a large number of human cases, plans for influenza surge capacity could be activated to accommodate healthcare facility needs. These plans include diverting ill persons to other facilities, implementing triage protocols in urgent care settings, and encouraging persons with mild or no illness ('worried well') to remain at home. Mosquito control on-site should be considered at healthcare facilities with large numbers of cases. Local vector control agencies should collaborate with local public health to determine the need for vector control management around healthcare facilities.

Guidelines for which individuals should seek medical care in the event of an outbreak, as well as suggested triage protocols for healthcare facilities, can be found in the PAHO/CDC and WHO guidelines found in the appendix of this document^{4,21,29}.

Outreach to Pregnant Women

In the event of Zika virus transmission, additional outreach and prevention actions for pregnant women should be considered due to the risk for congenital or perinatal Zika virus transmission. Potential activities include messaging about disease transmission through mosquitoes and sexual contact, enhanced prevention through mosquito control or dissemination of Zika prevention kits, Zika testing and counseling during pregnancy, and long-term follow-up of women and infants with Zika virus infection.

To understand more about Zika virus infection during pregnancy, the Centers for Disease Control and Prevention (CDC) established a national US Zika Pregnancy Registry. The Arizona Department of Health Services is participating in the Registry and has been working with county health departments to collect information about pregnancy and infant outcomes. Data from the Registry may provide information on the level of risk, timing of risk, and spectrum of outcomes associated with Zika virus infection during pregnancy. This information can then be used to direct testing, evaluation,

and management of pregnant women and their babies. Steps for county health departments to report possible Zika infections in pregnancy can be found [here](#).

Incident Command System

If an outbreak occurs, public health agencies are encouraged to utilize the incident command system called the Public Health Incident Command System (PHIMS) to manage the incident. The ADHS Health Emergency Operations Center (HEOC) can be activated to respond. The PHIMS system is compliant with the National Incident Management System (NIMS) and is divided into four functional areas: Operations, Planning, Logistics, and Finance. For more specific information about PHIMS operation, please see the ADHS HEOC Standard Operating Procedures and Emergency Response Plan (EPR)⁴⁵. The major operational components of the emergency operations structure include epidemiology, vector control, and communications. Epidemiology and disease control staff should work closely with all operational components. Each group should provide reports to assess progress and track updates. All groups should meet regularly to ensure consistency of information and response plans, including but not limited to, data points (such as incidence rate, geographic factors, etc.), activities, and messaging to stakeholders. Coordination is paramount to avoid confusion during the outbreak response

Public Health Response Scenarios

Scenario 1: Risk for imported cases

Messaging

- € Develop educational materials, such as fact sheets and frequently asked questions
- € Inform key stakeholders (healthcare partners, vector control officials, and the public) about available resources and guidelines
- € Provide information to the public about prevention and risk reduction while traveling
- € Disseminate prevention-based educational material, such as instructing the public about how to protect themselves and their homes from mosquitoes
- € Provide education and messaging to healthcare partners

Case Investigation and Surveillance

- € Closely investigate cases with travel history to areas where chikungunya, dengue, or Zika were reported
- € Educate suspect cases about the need to avoid mosquito contact to prevent disease transmission
 - Consider active case finding among household members
- € Facilitate confirmatory laboratory testing for suspect and probable cases
- € Track the number and distribution of travel-associated cases
 - Identify risk factors and perform descriptive analysis of cases

- € Ensure vector control is notified of areas where cases reside
- € Collaborate with vector control counterparts to compare imported human disease cases and mosquito surveillance results

Other Activities

- € Consider outreach to partners to develop collaborative response activities
- € Develop plans for medical surge capacity at healthcare facilities or laboratories
- € Anticipate sensitive issues, including:
 - Safety of increased pesticide application near homes
 - Cost of control measures
 - Potential for bloodborne transmission through transfusions

Scenario 2: Response to locally-acquired cases

Messaging

- € Notify media and raise public awareness through press releases about locally acquired cases
- € Increase public messaging about key topics:
 - Source reduction and mosquito avoidance
 - Disease symptoms and healthcare seeking recommendations
 - Local public health contacts
- € Consider enhanced outreach and education in areas with known human cases
- € Provide additional outreach to healthcare providers about diagnostic testing and treatment recommendations

Case Investigation and Surveillance

- € Consider methods for enhanced disease surveillance
 - Active case finding or household-based cluster investigations in communities where cases are identified
 - Enhanced laboratory surveillance
 - Enhanced screening for febrile illnesses in healthcare settings
- € Maintain up-to-date line list(s) of imported and locally-acquired cases
 - Consider use of Outbreak Module in MEDSIS
- € Continue to track the number and spatial distribution of cases
- € Describe key epidemiological and clinical features of cases
 - Assess clinical severity and impact on society
- € Identify circulating virus types
- € Continue collaboration with vector control
 - Collaborative outreach and education about source reduction

- Map human cases and *Aedes aegypti* mosquito surveillance data to identify high-risk areas
- Target high-risk areas for vector control operations


Other Activities

- € Consider ICS activation to organize public health response
- € Communicate with blood banks about risk of disease transmission through transfusion; consider screening donors for disease

Scenario 3: Recovery

- € Finalize line-lists of imported and locally acquired cases
 - Close outbreaks within 30 days of completion
- € Describe key epidemiologic and clinical features discovered during the outbreak
- € Scale down interventions to a sustainable level for education dissemination, vector control, etc.
 - Continue collaboration with vector control and the communications branch
- € Evaluate and assess the effectiveness of disease surveillance and control efforts

Locations of *Aedes aegypti* in Arizona, 2004-2016



VII: VECTOR SURVEILLANCE AND RESPONSE

Aedes aegypti Epidemiology

Arizona Arboviral Handbook for Chikungunya, Dengue, and Zika Viruses


Aedes species mosquitoes are widespread worldwide, from tropical to arctic regions⁴⁶. Of the potential *Aedes spp.* mosquito vectors, only two are known to be established in the United States: *Aedes aegypti* and *Aedes albopictus*^{5,47}. In Arizona, *Ae. aegypti* mosquitoes have been identified in multiple areas, including Maricopa, Pinal, Pima, Gila, Graham, Cochise, Santa Cruz, Yavapai, and Yuma counties¹⁰. Current data suggest the *Aedes albopictus* is not found anywhere in Arizona¹⁰. Arizona is home to other *Aedes* species, such as *Aedes vexans*, but these species have never been implicated as chikungunya, dengue, or Zika virus vectors and will not be discussed in this document^{4,5,10,20,47}.

Ae. aegypti mosquitoes are a peridomestic species and have adapted to live around humans and their homes^{4,20}. They exhibit different behaviors than the mosquito species that transmit West Nile virus. These differences will be discussed further throughout this section and become important in the context of current capacities of local vector control agencies.

The map on the previous page includes the available data for *Aedes aegypti* presence in Arizona between 2004 and 2016. Much of the data was gathered during the process of West Nile virus surveillance using non-optimal traps for *Aedes aegypti*. This map might not be indicative of all *Ae. aegypti* locations throughout the state, particularly in the southern border region.

The map below shows the estimated range of *Aedes aegypti* and *Aedes albopictus* in the United States; these maps do not indicate that the mosquitoes have been found in all locations and do not necessarily represent risk for disease spread⁴⁷.

Estimated range of *Aedes aegypti* (left) and *Aedes albopictus* (right) in the United States, 2016*



Vector Surveillance Background

Vector surveillance is used for both technical and research purposes and provides information on potential viral distribution in the environment, as well as distribution

changes in time and space. The primary objectives of vector surveillance include the following:

- Determine the baseline population of the relevant vector species in time and space, and^{5,47,48}
- Track spatial and temporal changes in the vector's population, and^{5,47,48}
- Monitor the effectiveness of control interventions, and^{5,47,48}
- Determine which areas are at greatest risk for human disease introduction and transmission^{5,47,48}.

Mosquito surveillance can be divided into two categories: larval and pupal surveillance, and adult surveillance^{4,5,20,47}.



Aedes aegypti eggs, CDC

Larval and Pupal Surveillance

During larval or pupal surveillance, all water-holding containers and locations on a household or property are searched for *Aedes aegypti* immatures^{5,47}. Larval or pupal presence is determined, and species identification is confirmed. There are three indices currently used by the World Health Organization (WHO) to quantify findings of these surveys: house index (HI), container index (CI), and Breteau index (BI)²⁰. The following table describes these indices.

It should be noted that a systematic review of vector indices and dengue transmission found that single BI or HI indices were unreliable predictors for dengue transmission risk, as transmission occurred in areas below the recognized thresholds as well⁴⁹.

Larval surveillance is labor-intensive and is not an optimal form of standard or large-scale surveillance⁴⁶. It also requires cooperation with property owners, as *Aedes aegypti* are most often found in and around homes. This type of surveillance can be useful when investigating mosquito exposure of individual cases or clusters.

| Larval and Pupal Surveillance Indices | Definition | Formula | Notes |
|---------------------------------------|--|---|---|
| House index (HI) | Percentage of houses infested with larvae and/or pupae ^{5,20,47,48} . | $HI = \frac{\text{Number of Infested houses} \times 100}{\text{houses inspected}^{20}}$ | Percentage of houses infested with larvae and/or pupae ⁴⁷ . Best for population level data HI <1% may indicate low risk ⁴⁷ . |
| Container index (CI) | Percentage of water-holding containers infested with larvae and/or pupae ^{5,20,47,48} . | $CI = \frac{\text{Number of infested containers} \times 100}{\text{containers inspected}^{20}}$ | Indicates percent of infested containers ⁴⁷ . |
| Breteau index (BI) | Number of larvae/pupae infested containers per 100 houses inspected ^{5,20,47,48} . | $BI = \frac{\text{Number of infested containers} \times 100}{\text{houses inspected}^{20}}$ | Indicates number of infected containers per 100 homes ⁴⁷ . |

Adult Surveillance

Adult *Aedes aegypti* surveillance can be valuable in determining the effectiveness of adulticide control measures and seasonal trends^{5,20,47,48}. There are three primary methods of collection, which include landing counts, resting collections, and trappings. For **landing counts**, a human subject is used as bait and the numbers of feeding mosquitoes that land on the person are counted. The result should be expressed as landing rate per hour^{20,47,48}. This method is generally not employed for safety reasons^{20,47,48}. **Resting collections** are a safer option, in which a mouth or a battery-powered aspirator is used to capture adult mosquitoes at rest^{20,47,48}. The result is expressed as the number of adult mosquitoes per house^{20,47}. Much like larval and pupal sampling, these methods are both labor and time-intensive and should only be considered under certain circumstances, such as for risk assessments of individual cases or clusters^{20,47}. Adult mosquito **traps** are the least labor and time-intensive, and provide the most data^{20,47,48}.

To focus *Aedes aegypti* surveillance efforts, different statistical sampling methods can be used to develop estimates of community levels²⁰. Options to consider include the following:

- Simple random sampling²⁰,

- Systematic sampling (selecting every “nth” house)²⁰,
- Stratified random sampling (stratifying by populations and selecting randomly within strata)²⁰.
 - For example, stratifying populations by neighborhood, and randomly selecting “x” number of homes in each neighborhood based on population estimates²⁰. This can help ensure areas are equally represented²⁰. If arboviral disease cases are clustered in certain areas, additional *Aedes aegypti* surveillance efforts could be focused there.

A variety of traps can be used for *Aedes aegypti* surveillance; brief descriptions of several common types are included in the table below.

| Trap Type | Description |
|--------------------------|--|
| Sticky Traps | Visual or odor-baited traps that attract and trap adult mosquitoes to sticky surfaces ^{20,47} . |
| Oviposition Traps | <p>Traps are visually pleasing and odor-baited for mosquitoes. They often contain germination paper or another substrate on which ovipositing female mosquitoes can deposit eggs^{20,47,48}. The traps are checked weekly and the eggs are identified and counted^{20,47,48}.</p> <p>SpringStar Trap-N-Kill® is an example of a lethal ovitrap, in which the egg laying female cannot escape and is trapped inside and killed^{20,47,50}.</p> |
| BG Sentinel Traps | Adult mosquitoes are attracted to the odor-baited traps and are sucked into a black catch bag with a suction fan ^{5,47,51} . Air exits with ascending currents through the white mesh ^{51,52} . |
| CO2 Traps | Mosquitoes are attracted to the carbon dioxide and light used in the traps ⁵² . These traps were designed for <i>Culex</i> species mosquitoes, and are not optimal for <i>Aedes aegypti</i> ^{5,47,52} . |

The table below lists *Aedes aegypti* surveillance options, and pros and cons of each method^{5,20,47}.

| Surveillance Type | Life Stage | Pros | Cons |
|------------------------------|------------------|--|--|
| Larval/pupal sampling | Larval and pupal | <ul style="list-style-type: none"> ❖ Not resource intensive^{5,20,47} | <ul style="list-style-type: none"> ❖ Time intensive^{5,20,47} ❖ No information on adult populations^{5,20,47} ❖ No viral testing possible^{5,20,47} |
| Oviposition Traps | Egg | <ul style="list-style-type: none"> ❖ Not resource intensive^{5,20,47} ❖ Inexpensive^{5,20,47} ❖ Effectively provides presence and absence data^{5,20,47} | <ul style="list-style-type: none"> ❖ Time intensive^{5,20,47} ❖ Can only provide presence and absence data (not population density data)^{5,20,47} ❖ Species must be identified at egg stage, or reared to adulthood^{5,20,47} ❖ No viral testing possible^{5,20,47} |
| BG Sentinel Traps | Adult | <ul style="list-style-type: none"> ❖ Most effective trap for capturing <i>Aedes aegypti</i> mosquitoes^{5,47,52} ❖ Provides population density data^{5,48,52} ❖ Adult mosquitoes can be tested for virus^{5,47} | <ul style="list-style-type: none"> ❖ Very high initial cost^{5,47} ❖ Time intensive^{5,47} |
| CO2 Traps | Adult | <ul style="list-style-type: none"> ❖ Already frequently used in AZ¹⁰ ❖ Adults mosquitoes can be tested for virus⁵³ | <ul style="list-style-type: none"> ❖ Inefficient at capturing <i>Aedes</i> spp. mosquitoes^{5,47,52} ❖ Not ideal for population density estimates^{5,47,52} |

Vector Surveillance Guidelines

Because *Aedes aegypti* mosquitoes have short flight distances^{11,20}, residences of persons with chikungunya, dengue, or Zika virus infections are often used as an approximation of exposure locations^{29,47}. The caveat to this approach is that it requires vector control and public health agencies to wait for an increase in disease incidence before geographically targeted interventions can be implemented²⁹.

Viral testing of mosquitoes by RT-PCR for chikungunya, dengue, and Zika virus is available at the Arizona State Public Health Laboratory¹⁴; however, the value of *Ae. aegypti* mosquito testing for surveillance is not well defined. This is one of the major differences between West Nile virus surveillance and chikungunya, dengue, or Zika surveillance. Chikungunya, dengue, and Zika only amplify in humans and not birds, so human cases are believed to be the best indicators of circulating virus^{29,53}. However, viral testing of mosquitoes may be helpful under certain circumstances. This should be considered, for example, around the homes of identified locally acquired cases or clusters of travel-associated cases²⁹. It's also possible that effective viral testing of mosquitoes could be valuable within the context of a large and well-established vector surveillance program.

Enhanced vector surveillance should be considered in response to any increased risk factor, such as the first locally acquired case or a sharp increase in travel-associated cases^{29,47}. Enhanced surveillance is defined as any surveillance activities above what is routine; this will entail different actions for different communities. The following tables can be used as a statewide guideline for minimum expectations. The Vectorborne and Zoonotic Diseases Program within the Arizona Department of Health Services can assist with these activities.

Scenario 1: Risk for Imported Cases

- € Determine presence or absence of *Aedes aegypti* mosquitoes in community or region
 - Consider use of ovitraps and *Ae. aegypti*-specific adult traps (e.g., BG Sentinel traps)
- € Map mosquito surveillance results with GIS technology to better understand baseline levels and distribution
 - Areas with high *Aedes aegypti* populations should be targeted for education on source reduction and control measures, particularly during warm, wet seasons
- € Communicate with public health partners to learn where new or suspected human cases are located. Surveillance and control activities should be focused in these areas in addition to routine surveillance and control, and:
 - Environmental investigation and source reduction education at case households
 - *Aedes aegypti* trapping in and around case households
 - Adulticide spraying (handheld sprayer) in 150m radius around case households
- € Collaborate with public health partners to compare maps of known *Ae. aegypti* distribution and imported human disease cases.

- € Continue routine surveillance in other areas
- € Provide public education about *Aedes aegypti* mosquitoes and source reduction; consider community-wide cleanup campaigns to reduce or eliminate sources of standing water

Scenario 2: Response to locally-acquired cases

- € Immediately implement enhanced vector surveillance and control in areas with known human cases
 - Perform *Aedes aegypti* trapping (ovitrap and adult traps) around case households and at other homes in neighborhood (at least 150m radius)
 - Perform environmental investigations in affected neighborhoods to educate homeowners about source reduction
 - Use adulticide sprays (handheld) in and around case households
 - Consider ultra-low volume spraying in areas with large *Aedes aegypti* populations and locally-acquired cases
- € Continue close communication and collaboration with public health officials to identify affected areas and focus response efforts
 - The localized enhanced surveillance and control measures should be continued for three mosquito incubation cycles (i.e. 45 days) following the last identified case
 - Compare maps of known *Ae. aegypti* distribution and known human cases.
- € Continue routine surveillance, education, and source reduction efforts in other areas

Scenario 3: Recovery

- € Scale down response phase activities
 - Initiate only after a demonstrated decrease in positive surveillance results (as determined by vector control data) and human disease cases (as determined by epidemiologic data)
- € Evaluate the effectiveness of vector control efforts with monitoring and evaluation procedures
- € Continue routine surveillance procedures
- € Continue collaboration with epidemiology and communications branches

All surveillance data should be entered into a standardized spreadsheet used for mosquito surveillance results reporting. The official spreadsheet is found in the appendix of this document. These results should be e-mailed to the Arizona Department of Health Services as an Excel file. The results from individual jurisdictions can then be integrated into a statewide mosquito surveillance report to be issued by ADHS on a consistent basis¹⁰. This report will help local partners keep abreast of mosquito activity throughout the state.

Vector Control Guidelines

Vector control is the single most important intervention during an outbreak^{20,29,47}. *Ae. aegypti* mosquitoes have unique behavioral characteristics and ecological preferences that can help target interventions^{4,5,20,47}.

Control for *Ae. aegypti* mosquitoes is challenging because they are primarily outdoor daytime biters that live near human habitats^{4,20,29,47}. Removing larval habitats is considered the most effective way to reduce *Ae. aegypti* populations^{4,20,29,47}. This is termed **source reduction**^{4,20,29,47,48}. *Ae. aegypti* oviposit (lay eggs) primarily in man-made containers filled with water, although suitable natural containers can also serve as mosquito breeding areas^{4,20,29,47,48}. One of the best methods for source reduction is for residents to ensure there are no containers near the home that are uncovered and filled with water, or have the potential to hold water^{4,20,29,47,48}. For source reduction, education is the best intervention^{4,20,29,47,48}. Educating people on how and why to protect themselves from mosquitoes will foster a greater sense of self-reliance and accountability among the public.

Ae. aegypti mosquitoes have relatively short flight distances from their birthplaces^{11,20,29}. This enhances the value of source reduction, as they will not fly great distances to reestablish elsewhere^{11,20,29}. However, it should be noted that human transportation activity assists in mosquito transport through contaminated containers, with tires as a key example⁴⁷.

Although source reduction is a necessary first line of defense, **during an outbreak** additional actions may be needed^{29,47,48,53}. Insecticides are also available, and include the following:

- Organophosphates (fenthion, temephos, and pirimphos-methyl)^{4,20,48},
- Spinosin based products^{4,20,48},
- Insect growth regulators (methoprene, pyriproxyfen and diflubenzuron)^{4,20,48},
- Biological control (*Bacillus thuringiensis israelensis*, *Bacillus sphaericus* and compounds derived from [*Saccharopolyspora spinosa*](#))^{4,20,48},
- Insecticidal oils^{4,20,48}.

Granular applications affect young larvae as they emerge from their egg state because of the longer chemical release period^{4,20,48}. These treatments can be done pre- or post-flooding^{20,29,48}. When applied before flooding, organophosphates will land on the dry ground, and only later become activated when the area becomes flooded with water^{20,48}. An exception is temephos, which is labeled to be applied directly to water⁵⁴. This happens concurrently with the reactivation of *Ae. aegypti* eggs that had previously been inactive on dry ground^{20,48}. *Ae. aegypti* eggs are typically laid just above the water line on damp substrates^{4,20,48,55}. The eggs are extremely hardy and can withstand

desiccation for anywhere from months to over a year, and will reactivate upon contact with water⁵⁵.

Ultra-low volume (ULV) aerial or ground-based spraying of organophosphates (malathion, fenitrothion, pirimiphos-methyl or pyrethroids) are often considered ineffective at controlling urban mosquito species, such as *Ae. aegypti*⁴⁸. Recent evidence, including mosquito control efforts during an outbreak of locally-acquired Zika virus in Florida during 2016, suggests ULV applications are effective at rapidly reducing transmission risk in outbreak settings, even when applications occur at night^{48,56}. This method should be considered if there is a confirmed case of local, mosquito-borne transmission of chikungunya, dengue, or Zika virus infection, or if *Ae. aegypti* population numbers are exceptionally high.

Another option for adult *Ae. aegypti* control includes use of a handheld sprayer to apply insecticide around the homes and yards of human cases and their neighbors^{29,48}. However, if locally acquired cases are identified, this method should be strongly considered to treat limited areas associated with an index case of disease^{29,48}.

Insecticide resistance may develop with frequent use of insecticides^{5,29,48}. Conducting systematic testing for resistance can be useful to select an insecticide that will be most effective^{5,29,48}. The CDC Bottle Bioassay can be used to assess resistance and to identify resistance mechanisms^{5,48}.

Barrier pesticide treatments provided by commercial pest control organizations can also be considered^{20,48}. These aim to control roosting mosquitoes, and could be incorporated into routine door/yard pest maintenance packages sold by private parties^{20,48}.

The following table looks at the different *Ae. aegypti* control options, and when to implement each.

| Control Type | When and Where to Implement |
|--------------------------------|--|
| <p>Source reduction</p> | <ul style="list-style-type: none"> ❖ Year round^{4,20,29,47,48} ❖ Relies on public education and personal responsibility^{4,20,29,47,48} ❖ Target education to known cases and case neighborhoods^{4,20,29,47,48} |
| <p>Larvicide</p> | <ul style="list-style-type: none"> ❖ Should be used in response to vector surveillance data^{4,20,29,47,48} ❖ Can be used to treat standing water that is not removable^{4,20,29,47,48} ❖ Target towards known cases and case neighborhoods^{4,20,29,47,48} |
| <p>Adulticide</p> | <ul style="list-style-type: none"> ❖ May be useful to rapidly reduce transmission risk in outbreak settings^{29,47,56} ❖ Should be used in response to vector and human surveillance data^{29,47} ❖ When used, target to known cases and case neighborhoods^{29,47} |

Recommendations for Local Vector Control Staff

The recommended standards for *Ae. aegypti* surveillance and control are highly dependent upon the resources of each community; however, general suggestions are outlined below. Routine mosquito surveillance control should be conducted consistently and throughout the year^{5,29,47,48}. Control actions can be escalated as needed based on surveillance data^{5,29,47,48}. The level of baseline surveillance will depend upon available resources.

Regardless of the scope of activities, a few key principles should always be considered. For routine surveillance, it is important that activities are done at **consistent locations** to enable comparisons across both space and time^{5,29,47,48}. *Ae. aegypti* surveillance is best conducted near human homes, and particularly near known disease cases^{5,29,47,48}. If resources allow, surveillance should be conducted yearlong in densely populated areas, with increased vigilance during warm rainy seasons^{5,29,47,48}. It is important to document the number of mosquitoes collected, trap type, species identification of all specimens, and any testing performed^{5,47}.

The number and distribution of traps used should be decided based on results of past surveillance, incidence of human cases in the area, and resource availability. Although BG Sentinel traps are best for capturing *Ae. aegypti* adults, they are also expensive and resource-intensive^{5,47,48,52}. They are also prone to theft and vandalism. Oviposition traps are a good alternative and can provide adequate presence and absence data^{20,76,48}. At a minimum, already available non-optimal traps, such as CO₂ traps used for *Culex spp.* surveillance can be utilized. Although results cannot definitely determine the presence of *Ae. aegypti*, CO₂ trap results can be valuable when other options are not available. By hanging the trap lower to ground, during the daytime, and near homes the likelihood to catching *Ae. aegypti* is increased^{5,47,52,53}.

Mosquito Surveillance Platform

Since 2019, Arizona has adopted the [VectorSurv](#) (ArizonaSurv) online interface for managing and analyzing surveillance and control data related to mosquitoes. Find more Arizona-specific information [here](#), including the [ArizonaSurv Reference Guide](#).

Mosquito submission instructions for testing at the State Lab can be found [here](#).

Legal Authority for Vector Control Response

[ARS 36-601](#) is the nuisance statute⁵⁷. This is under state authority, but is delegated to the county health departments. Locals also have some additional authority under [36-602](#)⁵⁸.

[Communicable disease rules](#), which specify reporting requirements and control measures, are AAC R9-6-202, 203, 204, 205 and AAC R9-6-323 (dengue) and AAC R9-6-391 (WNV)⁵⁹.

The control measures are only related to epi investigation; mosquito control is not included at this time⁵⁹.

The Role of Public Education

Aedes aegypti control is highly dependent on the actions of community members to eliminate sources of standing water where eggs and larvae can develop^{4,5,20,29,47,48}. Many breeding sites are found in homes and backyards, and prevention and control efforts should emphasize reduction of water-holding containers^{4,5,20,29,47,48}. In addition, personal protection from mosquitoes is critical in preventing bites^{4,5,20,29,47,48}.

Public education and community engagement is a necessary part of *Aedes aegypti* control, and prevention of mosquito bites^{4,5,20,29,47,48}. Messaging will be discussed further in the following section, but key messages should address the following topics^{4,5,20,29,47,48}.

- Source reduction: learning where mosquitoes oviposit and how to eliminate potential oviposition sites from in and outside the home^{4,5,20,29,47,48}.
- Correct use of insect repellent or long-sleeved shirts and pants when outdoors^{4,5,20,29,47,48}.
- Use of intact screens in windows and doors^{4,5,20,29,47,48}.

VIII: OUTBREAK COMMUNICATIONS

Public Information During a Potential or Ongoing Outbreak:

A necessary component of successfully managing a disease outbreak or potential outbreak is communication with stakeholders²⁹. For a chikungunya, dengue, or Zika outbreak, all community members in and around the affected area are considered stakeholders²⁹. It is necessary to inform them about concerns over a potential or ongoing outbreak because the public must participate in vector control²⁹. Because *Aedes aegypti* reside in and around homes this is a pivotal step in disease prevention^{5,29,47,48}. The public should be kept informed in a timely manner, but steps must also be taken to avoid public panic and spread of misinformation²⁹. There should be a close partnership between media, public health, and vector control²⁹. In addition to a close partnership with media outlets, public health should also launch public education campaigns and have a strong social media presence²⁹. This should be initiated when cases identified in the county, even if they are travel-associated²⁹. Outreach and education should be scaled up if a locally acquired case is identified, and scaled down following three incubation periods (i.e. 45 days) with no newly reported cases²⁹.

Public Education

Public education should focus on three pivotal areas:

- **Disease information**
 - *Who is at risk?* Anyone with exposure to mosquitoes²⁹.
 - i. Emphasize the true risk of disease, as well as the appropriate statistics²⁹.
 - *How is it transmitted?* Via a mosquito vector that bites during the day and lives around houses²⁹.
 - *What are the symptoms?* Most commonly, fever, rash, joint pain, headache, body aches, etc.²⁹.
 - *What is the treatment?* No specific treatment, disease usually resolves on its own²⁹. Dengue fever may require supportive therapy in a hospital setting²⁰.
 - *How dangerous is it?* Symptoms can be severe and very unpleasant^{4,20}. Dengue may be fatal^{20,21}. Sometimes symptoms of chikungunya can linger after the disease resolves, such as arthritis lasting for months following illness⁴. Adults over 65 years of age, those with health conditions, and newborns, are at risk for more severe disease manifestations^{4,20,21}.
- **Personal protection against mosquito vectors**
 - *How do I protect myself?* Always wear an insect repellent while outside²⁹.
 - i. Also wear long sleeves and long pants when outdoors²⁹.

- **Property and home protection against mosquito vectors**

- *How do I protect my home and family?* Always use air conditioning instead of leaving doors or windows open, or make sure all doors and windows have intact screens²⁹.
 - i. Dump any standing water in or around your home^{5,29,47,48}. Mosquitoes can lay eggs in there! If you cannot dump it (i.e. a pool, pond, etc.) treat it with the appropriate pesticides^{5,29,47,48}.

Educational materials can be found through the Centers for Disease Control and Prevention, Arizona Department of Health Services, and local health department websites. The goal of public messaging is to help the public make informed decisions, encourage positive behavior change, and maintain a dialog and culture of trust between stakeholders (i.e. the public) and authorities. As chikungunya and Zika viruses are new to the Americas, and dengue to Arizona, public knowledge is likely low. A focused educational campaign is essential.

Social Media Messaging

Social media messaging is defined as any messaging shared on a social media platform. It allows for information to be dispersed to a wider audience and then shared further by interested parties. Infographics and other educational materials can be shared on Facebook, Twitter and LinkedIn pages. The more this information is shared, the wider the audience will be.

During an increase in disease cases or vector populations, relevant materials should be shared more frequently so stakeholders have timely access to relevant and factual information. By sharing up-to-date incidence information and prevention messages, social media messaging can also be used to allay fears about the emerging disease²⁹.

Messaging for Healthcare Providers

Communication with healthcare providers is critical in all phases of preparedness and response for mosquito-borne disease threats^{4,20,21,29}. These messages should include the signs and symptoms of chikungunya, dengue, or Zika fever, diagnostic testing, reporting, and treatment recommendations^{4,20,21,29}.

Messaging for Vector Control

Communication with vector control agencies in all stages of the response is necessary to share information about vector presence, epidemiologic updates, and mosquito surveillance and control guidelines^{5,29,47,48}. Vector control agencies should be encouraged

to conduct surveillance for *Aedes aegypti*, and develop plans for local response^{5,47}. Surveillance findings can be shared at the state level through the Arbonet database.

Messaging for At-Risk Populations

Certain populations, including newborns, adults over 65 years of age, and persons with underlying medical conditions (high blood pressure, diabetes, and heart disease), are at higher risk for severe disease and death from arboviral disease^{4,20,21,23,29}. Special outreach and messaging should be considered for these groups. This could include outreach through healthcare facilities to at-risk populations, as well as targeted messaging through social media.

Communication Response Scenarios

Scenario 1: Risk for imported cases

- € Develop educational materials including fact sheets, frequently asked questions, press releases, and talking points for chikungunya, dengue, and Zika, as well as *Aedes aegypti* mosquitoes
- € Inform key stakeholders about preparedness materials and guidelines
 - Healthcare facilities
 - Local public health partners
 - State health agencies and partners
- € Begin dissemination of prevention-oriented educational materials through various formats
 - Printed materials
 - Websites
 - Social media messaging
 - Text messaging
- € Develop a strong relationship with journalists and media partners. Media opportunities can be used to educate the public and avoid spread of misinformation
- € Anticipate sensitive issues involved in the response and address them proactively. Some potential issues include:
 - Safety and risks associated with the increased pesticide application near homes
 - Large numbers of at-risk people inundating healthcare settings
 - Cost of control measures
 - Stigma issues associated with binational transmission

Scenario 2: Response to locally-acquired cases

- € Issue local and statewide press releases to raise community awareness
 - Use a consistent spokesperson (preferably a local representative) as much as possible
 - Ensure information is released promptly
 - Use opportunity to promote source reduction and mosquito avoidance
- € Increase efforts to disseminate educational materials to the public about mosquito control and disease symptoms
- € Initiate consistent and frequent messaging via websites and social media platforms.
 - Ensure messaging is consistent from different partners (state and local levels)
- € Intensify communications with healthcare providers. Messaging should include disease information, differential diagnoses, and reporting requirements. Provide up to date incidence rates. This may be done via hospital associations, professional groups, or network notices determined during the preparedness phase
 - Instruct healthcare providers to tell patients to AVOID mosquito contact while ill to assist in disrupting the furthering of disease transmission

Scenario 3: Recovery

- € Scale down interventions to a sustainable level for disease surveillance, education dissemination, vector control, etc.
- € Communicate the decreasing threat of disease transmission to the public
- € Evaluate and assess the effectiveness of risk communications and communications between agencies during the response phase

IX: APPENDIX

Investigation Forms

- ❖ Arizona State Public Health Laboratory (ASPHL) Submission via ETOR:
<https://www.azdhs.gov/preparedness/state-laboratory/shipping-receiving/index.php#forms-clinical>

Please see the following links for chikungunya, dengue, and Zika investigation forms. All case investigation forms are available on the [ADHS Disease Investigation Resources webpage](#).

- ❖ [Chikungunya case investigation form](#)
- ❖ [Dengue/Zika case investigation form](#)

Chikungunya, dengue, and Zika morbidities are also available in MEDSIS for case investigators.

ADHS Educational Materials and Resources

- ❖ [Mosquito Breeding Sites Infographic](#)
- ❖ [Know the Facts Infographic](#)
- ❖ [Zika Prevention Counseling for Clinicians](#)
- ❖ [Traveling and Going to Mexico Infographics \(in English and Spanish\)](#)
- ❖ Modifiable versions of the following documents are also available by request:
 - Locally acquired case press release
 - Locally acquired case Health Alert Network notification
 - Talking points
 - Household investigation forms
 - Individual questionnaire forms
 - Adult and child consent forms for community investigations
 - Adult and immature mosquito assessment forms

ADHS and County Health Department Contacts

Arizona Department of Health Services

Office of Infectious Disease Services: See [ADHS Contact Information](#)

County Public Health Communicable Disease Contact List: See [County Contact List](#).

Helpful Surveillance Resources

1. **Reporting Page:** [ADHS - Epidemiology & Disease Control - Communicable Disease Reporting - Home \(azdhs.gov\)](#)
2. **Legal Requirements:** [ADHS - Epidemiology & Disease Control - Legal Requirements \(azdhs.gov\)](#)
3. **Case Definitions:** [ADHS - Epidemiology & Disease Control - Disease Investigation Resources - Case Definitions \(azdhs.gov\)](#)
4. **Disease Investigation Forms:** [ADHS - Epidemiology & Disease Control - Disease Investigation Resources - Disease Reporting & Investigation Forms \(azdhs.gov\)](#)
5. **Statistics:** [ADHS - Epidemiology & Disease Control - Disease Data, Statistics & Reports - Data & Statistics Tables \(azdhs.gov\)](#)
6. **VectorSurv:** <https://vectorsurv.org/>

References

1. Kimberlin DW, Brady MT, Jackson MA, Long SS. Arboviruses. In: 2015 report of the committee on infectious disease. 30th ed. Elk Grove, IL: American Academy of Pediatrics; 2015. p. 240-246.
2. Staples E, Powers A. Arboviral Arthritis and Rash. In: Heymann DL, editor. Control of communicable diseases manual. 20th ed. Washington, DC: American Public Health Association; 2015. p. 33-36.
3. Powers AM, Brault AC, Tesh RB, Weaver SC. Re-emergence of chikungunya and o'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. *Journal of General Virology*. 2000Jan;81(2):471–9.
4. Preparedness and response for Chikungunya virus introduction in the Americas. Washington, DC: Pan American Health Organization; 2011. Available from: http://www1.paho.org/hq/dmdocuments/CHIKV_English.pdf
5. Guidelines for *Aedes aegypti* and *Aedes albopictus* surveillance and insecticide resistance testing in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 2016. Available from: <https://www.cdc.gov/zika/pdfs/guidelines-for-aedes-surveillance-and-insecticide-resistance-testing.pdf>
6. Staples JCAE, Breiman RF, Powers AM. Chikungunya Fever: An Epidemiological Review of a Re-Emerging Infectious Disease. *Clinical Infectious Diseases*. 2009;49(6):942–8.
7. Chikungunya in the French part of the Caribbean isle of Saint martin [Internet]. World Health Organization; 2013Dec10 [cited 2017May19]. Available from: http://www.who.int/csr/don/2013_12_10a/en/
8. Weaver SC. Arrival of Chikungunya Virus in the New World: Prospects for Spread and Impact on Public Health. *PLoS Neglected Tropical Diseases*. 2014;8(6).
9. Chikungunya Virus: Geographic Distribution [Internet]. Centers for Disease Control and Prevention; 2016Aug3 [cited 2017May19]. Available from: <https://www.cdc.gov/chikungunya/geo/index.html>
10. Mosquitoes of Arizona [Internet]. Arizona Department of Health Services [cited 2017Jun29]. Available from: <http://www.azdhs.gov/preparedness/epidemiology-disease-control/mosquito-borne/index.php#mosquitoes-of-arizona>

11. Dengue control: The mosquito [Internet]. World Health Organization [cited 2017May19]. Available from: <http://www.who.int/denguecontrol/mosquito/en/>
12. Chikungunya Virus: Clinical Evaluation and Disease [Internet]. Centers for Disease Control and Prevention; 2015Aug3 [cited 2017May19]. Available from: <https://www.cdc.gov/chikungunya/hc/clinicalevaluation.html>
13. Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV. Increased Mortality Rate Associated with Chikungunya Epidemic, Ahmedabad, India. *Emerging Infectious Diseases*. 2008;14(3):412–5.
14. Guide to Laboratory Services: Microbiology [Internet]. Arizona Department of Health Services. 2017Jan20 [cited 2017May19]. Available from: <http://azdhs.gov/documents/preparedness/state-laboratory/public-health-microbiology/lab-guide.pdf>
15. Chikungunya Virus: Diagnostic Testing [Internet]. Centers for Disease Control and Prevention; 2016Jan20 [cited 2017Jun30]. Available from: <https://www.cdc.gov/chikungunya/hc/diagnostic.html>
16. Arboviral Diseases, Neuroinvasive and Non-neuroinvasive - 2015 Case Definition [Internet]. National Notifiable Diseases Surveillance System (NNDSS). Centers for Disease Control and Prevention; [cited 2017May19]. Available from: <https://wwwn.cdc.gov/nndss/conditions/arboviral-diseases-neuroinvasive-and-non-neuroinvasive/case-definition/2015/>
17. Case definitions. In: Case Definitions for Reportable Communicable Morbidities – 2017 [Internet]. Arizona Department of Health Services. [cited 2017May19]. Available from: <http://www.azdhs.gov/documents/preparedness/epidemiology-disease-control/disease-investigation-resources/case-definitions.pdf>
18. Kimberlin DW, Brady MT, Jackson MA, Long SS. Dengue. In: 2015 report of the committee on infectious disease. 30th ed. Elk Grove, IL: American Academy of Pediatrics; 2015. p. 322-325.
19. Margolis H, Tomashek K, Hunsperger E, Muñoz J. Dengue. In: Heymann DL, editor. *Control of communicable diseases manual*. 20th ed. Washington, DC: American Public Health Association; 2015. p. 144-150.

20. Dengue: guidelines for diagnosis, treatment, prevention, and control. Geneva: World Health Organization; 2009. Available from: http://apps.who.int/iris/bitstream/10665/44188/1/9789241547871_eng.pdf
21. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. New Delhi, India: World Health Organization Regional Office for South-East Asia; 2011. Available from: http://apps.searo.who.int/pds_docs/B4751.pdf?ua=1
22. Dengue Fever—Information and Data [Internet]. Arizona Department of Health Services [cited 2017Jun30]. Available from: <http://www.azdhs.gov/preparedness/epidemiology-disease-control/mosquito-borne/index.php#dengue-info-data>
23. Handbook for Clinical Management of Dengue. Geneva: World Health Organization; 2012. Available from: http://www.wpro.who.int/mvp/documents/handbook_for_clinical_management_of_dengue.pdf
24. Dengue: Laboratory Guidance and Diagnostic Testing [Internet]. Centers for Disease Control and Prevention; 2016Jan20 [cited 2017Jun30]. Available from: <https://www.cdc.gov/dengue/clinlab/laboratory.html>
25. Dengue Virus Infection - 2015 Case Definition [Internet]. National Notifiable Diseases Surveillance System (NNDSS). Centers for Disease Control and Prevention; [cited 2017May23]. Available from: <https://wwwn.cdc.gov/nndss/conditions/dengue-virus-infections/case-definition/2015/>
26. Zika Virus: Information for Clinicians [Internet]. Centers for Disease Control and Prevention; 2017May5 [cited 2017May24]. Available from: <https://www.cdc.gov/zika/hc-providers/training/training.html> ; <https://www.cdc.gov/zika/hc-providers/women-reproductive-age.html>
27. Key Messages—Zika Virus Disease. Centers for Disease Control and Prevention; 2017May17 [cited 2017May24]. Available from: <https://www.cdc.gov/zika/pdfs/zika-key-messages.pdf>

28. Zika virus, Microcephaly and Guillain-Barré Syndrome Situation Report. World Health Organization; 2016Dec29 [cited 2017May24]. Available from:
<http://apps.who.int/iris/bitstream/10665/252672/1/zikasitrep29Dec16-eng.pdf?ua=1>
29. CDC Zika Interim Response Plan. Centers for Disease Control and Prevention; 2017May [cited 2017May24]. Available from: <https://www.cdc.gov/zika/pdfs/zika-draft-interim-conus-plan.pdf>
30. World Map of Areas with Risk of Zika [Internet]. Centers for Disease Control and Prevention; 2017Jun7 [cited 2017Jul7]. Available from:
<https://wwwnc.cdc.gov/travel/page/world-map-areas-with-zika>
31. Dengue Fever [Internet]. Arizona Department of Health Services [cited 2017May24]. Available from: <http://www.azdhs.gov/preparedness/epidemiology-disease-control/mosquito-borne/index.php#dengue-home>
32. Chikungunya [Internet]. Arizona Department of Health Services [cited 2017May24]. Available from: <http://www.azdhs.gov/preparedness/epidemiology-disease-control/mosquito-borne/index.php#chikungunya-home>
33. Mosquito-Borne Diseases [Internet]. Arizona Department of Health Services [cited 2017May24]. Available from: <http://www.azdhs.gov/preparedness/epidemiology-disease-control/mosquito-borne/index.php>
34. Vorou R. Zika virus, vectors, reservoirs, amplifying hosts, and their potential to spread worldwide: what we know and what we should investigate urgently. *International Journal of Infectious Diseases*. 2016;48:85–90.
35. Sharma A, Lal SK. Zika Virus: Transmission, Detection, Control, and Prevention. *Frontiers in Microbiology*. 2017Mar;8.
36. Hayes EB. Zika Virus Outside Africa. *Emerg Infect Dis*. 2009;15(9):1347-1350.
37. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika Virus and Birth Defects — Reviewing the Evidence for Causality. *New England Journal of Medicine*. 2016;374(20):1981–7.
38. Zika Virus Disease and Zika Virus Infection - 2016 Case Definition, Approved June 2016 [Internet]. National Notifiable Diseases Surveillance System (NNDSS). Centers for Disease Control and Prevention; [cited 2017May24]. Available from:
<https://wwwn.cdc.gov/nndss/conditions/zika/case-definition/2016/06/>

39. Rabe I. Zika Virus—What Clinicians Need to Know? [Internet]. Centers for Disease Control and Prevention. 2016Jan26 [cited 2017May24]. Available from: https://emergency.cdc.gov/coca/ppt/2016/01_26_16_zika.pdf
40. Staples JE, Hills SL, Powers AM. Chikungunya. In: CDC health information for international travel: the yellow book 2016 [Internet]. New York: Oxford University Press; 2016 [cited 2017May25]. Available from: <https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/chikungunya>
41. Tomashek KM, Sharp TM, Margolis HS. Dengue. In: CDC health information for international travel: the yellow book 2016 [Internet]. New York: Oxford University Press; 2016 [cited 2017May25]. Available from: <https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/dengue>
42. Chen TH, Staples JE, Fischer M. Zika. In: CDC health information for international travel: the yellow book 2016 [Internet]. New York: Oxford University Press; 2016 [cited 2017May25]. Available from: <https://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/zika>
43. Toolkit for Investigating Possible Local Mosquito-Borne Transmission of Zika Virus [Internet]. Centers for Disease Control and Prevention; 2017May5 [cited 2017Jul7]. Available from: <https://www.cdc.gov/zika/public-health-partners/epidemiologic-investigation-toolkit.html>
44. Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components. Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components. 2016. Available from: <https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM518213.pdf>
45. Emergency Response Plan– 2016 [Internet]. Arizona Department of Health Services. [cited 2017Jun06]. Available from: <http://azdhs.gov/documents/preparedness/emergency-preparedness/response-plans/adhs-emergency-response-plan.pdf>

46. Aedes [Internet]. Walter Reed Biosystematics Unit [cited 2017Jun29]. Available from: http://www.wrbu.org/mqID/mq_gnra/aedes.htm
47. Surveillance and Control of *Aedes aegypti* and *Aedes albopictus* in the United States. Atlanta, GA: Centers for Disease Control and Prevention. Available from: <https://www.cdc.gov/chikungunya/pdfs/Surveillance-and-Control-of-Aedes-aegypti-and-Aedes-albopictus-US.pdf>
48. Best Practices for Integrated Mosquito Management: A Focused Updated; 2017. American Mosquito Control Association. Available from: https://amca.memberclicks.net/assets/HomePage/amca%20guidelines%20final_pdf.pdf
49. Bowman LR, Runge-Ranzinger S, McCall PJ. Assessing the Relationship between Vector Indices and Dengue Transmission: A Systematic Review of the Evidence. PLoS Neglected Tropical Diseases. 2014Aug;8(5).
50. Mosquito Trap-N-Kill® [Internet]. SpringStar Inc; 2017 [cited 2017Jun29]. Available from: <https://www.springstar.net/products/mosquito-trap-n-kill-1-trap>
51. BG-Sentinel: Biogents' Professional Mosquito Trap [Internet]. Biogents. [cited 2017Jun29]. Available from: <http://www.bg-sentinel.com/>
52. Maciel-De-Freitas R, Eiras ÁE, Lourenço-De-Oliveira R. Field evaluation of effectiveness of the BG-Sentinel, a new trap for capturing adult *Aedes aegypti* (Diptera: Culicidae). Memórias do Instituto Oswaldo Cruz. 2006;101 (3):321–5.
53. West Nile Virus in the United States: Guidelines for Surveillance, Prevention, and Control; 2013Jun14. Fort Collins, Colorado: Centers for Disease Control and Prevention. Available from: <https://www.cdc.gov/westnile/resources/pdfs/wnvGuidelines.pdf>
54. Controlling Mosquitoes at the Larval Stage [Internet]. United States Environmental Protection Agency [cited 2017Jun30]. Available from: <https://www.epa.gov/mosquitocontrol/controlling-mosquitoes-larval-stage>
55. Yellow Fever Mosquito [Internet]. University of Florida: Institute of Food and Agricultural Sciences; 2013 [cited 2017Jun30]. Available from: http://entnemdept.ufl.edu/creatures/aquatic/aedes_aegypti.htm

56. Likos A, Griffin I, Bingham AM, Stanek D, Fischer M, White S, et al. Local Mosquito-Borne Transmission of Zika Virus — Miami-Dade and Broward Counties, Florida, June–August 2016. *MMWR Morbidity and Mortality Weekly Report*. 2016;65(38):1032–8.
57. Public Nuisances Dangerous to Public Health [Internet]. Arizona State Legislature [cited 2017Jun30]. Available from: <http://www.azleg.gov/ars/36/00601.htm>
58. Abatement of Nuisances, Sources of Filth and Causes of Sickness; Civil Penalty; Property Assessment; Procedure [Internet]. Arizona State Legislature [cited 2017Jun30]. Available from: <http://www.azleg.gov/ars/36/00602.htm>
59. Arizona Administrative Code [Internet]. 2013Sep30 [cited 2017Jun30]. Available from: http://apps.azsos.gov/public_services/Title_09/9-06.pdf

Epidemiological Profiles


Arizona Chikungunya Epi Profile 2008-2016

last updated 7/21/2017




Total confirmed and probable cases reported in this period: **45**



Cases of Chikungunya virus increased in 2014 and 2015.



Chikungunya is more commonly reported in summer months.



Chikungunya is more often found in residents of Maricopa, Pima and Yavapai Counties.




Arizona Department of Health Services
Office of Infectious Disease Services


Arizona Chikungunya Epi Profile 2008-2016

last updated 7/21/2017


Chikungunya cases are mostly females.



Chikungunya cases are mostly Hispanic or Latino.



Chikungunya cases are mostly 20 to 44 years old.



Arizona Department of Health Services
Office of Infectious Disease Services

Arizona Dengue Epi Profile 2008-2016

last updated 7/21/2017




Total confirmed and probable cases reported in this period: **167**


Cases of dengue virus increased in 2014.



Dengue is more commonly reported in the late-fall/winter months.



Dengue is more often found in residents of Yuma, Maricopa and Pima Counties.




Arizona Department of Health Services
Office of Infectious Disease Services


Arizona Dengue Epi Profile 2008-2016

last updated 7/21/2017

Dengue cases are mostly females.



Dengue cases are mostly Hispanic or Latinos.



Dengue cases are mostly 20-44 years old.



Arizona Department of Health Services
Office of Infectious Disease Services

Arizona Zika Epi Profile 2008-2016

last updated 7/21/2017




Total confirmed and probable cases reported in this period: **56**


Imported cases of Zika virus were first reported in 2016.



Zika cases peaked in August.



Imported cases of Zika are more often found in residents of Maricopa and Pima Counties.




Arizona Department of Health Services
Office of Infectious Disease Services


Arizona Zika Epi Profile 2008-2016

last updated 7/21/2017

Zika cases are mostly females.




Zika cases are mostly Hispanic or Latinos*.



* Excluding unknown race/ethnicity.

Zika cases are mostly 20-44 years old.



Arizona Department of Health Services
Office of Infectious Disease Services

